Eric J Topol

List of Publications by Year
in descending order

883 papers	122,737 citations	68 173 h-index	193 316 g-index
910 all docs	910 docs citations	910 times ranked	74931 citing authors

#	Article	IF	Citations
1	High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 2019, 25, 44-56.	15.2	2,938
2	Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2002, 288, 2411.	3.8	2,791
3	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	13.9	2,582
4	Prevalence of Asymptomatic SARS-CoV-2 Infection. Annals of Internal Medicine, 2020, 173, 362-367.	2.0	2,056
5	Tissue Factor, the Emerging Link Between Inflammation, Thrombosis, and Vascular Remodeling. Circulation Research, 2001, 89, 1-2.	2.0	1,239
6	Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2003, 290, 898.	3.8	1,200
7	Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet, The, 2003, 362, 697-703.	6.3	1,199
8	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 305, 1097.	3.8	1,185
9	The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics, 2018, 19, 581-590.	7.7	1,102
10	Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention<SUBTITLE>REPLACE-2 Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 289, 853.	3.8	1,074
11	Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia. New England Journal of Medicine, 1996, 335, 1333-1342.	13.9	1,042
12	Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure. JAMA - Journal of the American Medical Association, 2004, 292, 2217.	3.8	1,016
13	Aortocoronary Saphenous Vein Graft Disease. Circulation, 1998, 97, 916-931.	1.6	1,008
14	Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet, The, 2003, 361, 2017-2023.	6.3	994
15	Prognostic Value of Myeloperoxidase in Patients with Chest Pain. New England Journal of Medicine, 2003, 349, 1595-1604.	13.9	981
16	A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the American College of Cardiology, 2003, 41, 961-965.	1.2	957
17	Our Preoccupation With Coronary Luminology. Circulation, 1995, 92, 2333-2342.	1.6	945
18	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, The, 2002, 359, 189-198.	6.3	944

#	Article	IF	Citations
19	A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction. New England Journal of Medicine, 1987, 317, 581-588.	13.9	942
20	Human genetic variation and its contribution to complex traits. Nature Reviews Genetics, 2009, 10, 241-251.	7.7	942
21	A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. The Lancet Digital Health, 2019, 1, e271-e297.	5.9	930
22	Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction. Circulation, 1995, 91, 1659-1668.	1.6	901
23	Relationship of Blood Transfusion and Clinical Outcomes in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 1555.	3.8	894
24	State of Telehealth. New England Journal of Medicine, 2016, 375, 154-161.	13.9	882
25	The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genetics, 2004, 36, 233-239.	9.4	859
26	Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment Elevation. Circulation, 2000, 101, 2557-2567.	1.6	841
27	Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet, The, 1998, 352, 87-92.	6.3	789
28	Sex, Clinical Presentation, and Outcome in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 1999, 341, 226-232.	13.9	777
29	Profile and prevalence of aspirin resistance in patients with cardiovascular disease. American Journal of Cardiology, 2001, 88, 230-235.	0.7	760
30	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	1.2	752
31	Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine. New England Journal of Medicine, 1995, 332, 1553-1559.	13.9	748
32	Assessing the impact of population stratification on genetic association studies. Nature Genetics, 2004, 36, 388-393.	9.4	734
33	Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries. Circulation, 1996, 94, 1690-1697.	1.6	726
34	Recognition of the Importance of Embolization in Atherosclerotic Vascular Disease. Circulation, 2000, 101, 570-580.	1.6	720
35	Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 2005, 45, 246-251.	1.2	713
36	A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease. New England Journal of Medicine, 1993, 329, 221-227.	13.9	680

#	Article	IF	Citations
37	Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction. Circulation, 1998, 98, 734-741.	1.6	679
38	Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization. New England Journal of Medicine, 2001, 344, 1888-1894.	13.9	675
39	AI in health and medicine. Nature Medicine, 2022, 28, 31-38.	15.2	638
40	Risk Factors, Angiographic Patterns, and Outcomes in Patients With Ventricular Septal Defect Complicating Acute Myocardial Infarction. Circulation, 2000, 101, 27-32.	1.6	635
41	Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine, 2007, 13, 1176-1184.	15.2	601
42	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2205-2217.	13.9	596
43	Electrocardiographic Diagnosis of Evolving Acute Myocardial Infarction in the Presence of Left Bundle-Branch Block. New England Journal of Medicine, 1996, 334, 481-487.	13.9	577
44	The emerging field of mobile health. Science Translational Medicine, 2015, 7, 283rv3.	5.8	570
45	Common vs. rare allele hypotheses for complex diseases. Current Opinion in Genetics and Development, 2009, 19, 212-219.	1.5	568
46	9p21 DNA variants associated with coronary artery disease impair interferon-Î³ signalling response. Nature, 2011, 470, 264-268.	13.7	557
47	Failing the Public Health â€" Rofecoxib, Merck, and the FDA. New England Journal of Medicine, 2004, 351, 1707-1709.	13.9	553
48	Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 1759.	3.8	553
49	Cause of death in clinical research. Journal of the American College of Cardiology, 1999, 34, 618-620.	1.2	550
50	N -Terminal Proâ€"Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease. Circulation, 2003, 108, 275-281.	1.6	540
51	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. Circulation, 1999, 100, 14-20.	1.6	532
52	Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction. New England Journal of Medicine, 1995, 332, 1418-1424.	13.9	522
53	Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease Risk. New England Journal of Medicine, 2011, 364, 524-534.	13.9	519
54	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, The, 2004, 363, 1139-1146.	6.3	510

#	Article	IF	Citations
55	Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biology, 2009, 10, R32.	13.9	510
56	Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. BMJ, The, 2020, 368, m689.	3.0	509
57	Platelet GPIIb-IIIa blockers. Lancet, The, 1999, 353, 227-231.	6.3	508
58	Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2005, 294, 2581.	3.8	507
59	The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. Personalized Medicine, 2011, 8, 161-173.	0.8	507
60	Critical Issues in Peripheral Arterial Disease Detection and Management<subtitle>A Call to Action</subtitle>. Archives of Internal Medicine, 2003, 163, 884.	4.3	486
61	Deep learning-enabled medical computer vision. Npj Digital Medicine, 2021, 4, 5.	5.7	469
62	Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2008, 299, 1265.	3.8	463
63	Myonecrosis After Revascularization Procedures. Journal of the American College of Cardiology, 1998, 31, 241-251.	1.2	459
64	Sex Differences in Mortality Following Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2009, 302, 874.	3.8	440
65	Common variants in KCNN3 are associated with lone atrial fibrillation. Nature Genetics, 2010, 42, 240-244.	9.4	438
66	Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nature Biotechnology, 2009, 27, 1025-1031.	9.4	425
67	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimerâ€™s disease. Nature, 2014, 505, 550-554.	13.7	425
68	The Proportion of SARS-CoV-2 Infections That Are Asymptomatic. Annals of Internal Medicine, 2021, 174, 655-662.	2.0	423
69	Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion. Circulation, 1995, 91, 1923-1928.	1.6	416
70	Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Nonâ€“ST-Segment-Elevation Acute Coronary Syndromes. Circulation, 2001, 104, 2767-2771.	1.6	411
71	Can Mobile Health Technologies Transform Health Care?. JAMA - Journal of the American Medical Association, 2013, 310, 2395.	3.8	398
72	Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 171-179.	1.2	392

#	Article	IF	Citations
73	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery. JAMA - Journal of the American Medical Association, 2012, 307, 265-74.	3.8	386
74	Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1fn1This study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 406-413.	1.2	384
75	Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. Circulation, 2011, 124, 1132-1137.	1.6	381
76	Time from symptom onset to treatment and outcomes after thrombolytic therapy. Journal of the American College of Cardiology, 1996, 27, 1646-1655.	1.2	376
77	Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology, 2002, 90, 625-628.	0.7	376
78	Cell adhesion molecules in coronary artery disease. Journal of the American College of Cardiology, 1994, 24, 1591-1601.	1.2	375
79	Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. New England Journal of Medicine, 1999, 341, 319-327.	13.9	369
80	Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. Journal of the American College of Cardiology, 1995, 26, 668-674.	1.2	368
81	Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization<SUBTITLE>REPLACE-2 Randomized Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2004, 292, 696.	3.8	363
82	Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists. Circulation, 2001, 103, 201-206.	1.6	359
83	A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary Angioplasty. New England Journal of Medicine, 1987, 317, 1613-1618.	13.9	358
84	Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring. American Journal of Medicine, 2014, 127, 95.e11-95.e17.	0.6	358
85	Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomes. Journal of the American College of Cardiology, 1993, 22, 135-143.	1.2	353
86	Regional Variation across the United States in the Management of Acute Myocardial Infarction. New England Journal of Medicine, 1995, 333, 565-572.	13.9	351
87	Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease. Circulation, 1998, 98, 2829-2835.	1.6	346
88	Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug Discovery, 2003, 2, 15-28.	21.5	346
89	Mutation of MEF2A in an Inherited Disorder with Features of Coronary Artery Disease. Science, 2003, 302, 1578-1581.	6.0	344
90	Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile. Journal of the American College of Cardiology, 1992, 19, 926-935.	1.2	339

#	Article	IF	Citations
91	A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nature Genetics, 2006, 38, 68-74.	9.4	339
92	Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2018, 320, 146.	3.8	338
93	Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction. Circulation, 1997, 95, 846-854.	1.6	337
94	Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention. Circulation, 2001, 103, 961-966.	1.6	336
95	Hyperhomocysteinemia and Low Pyridoxal Phosphate. Circulation, 1995, 92, 2825-2830.	1.6	326
96	Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. American Heart Journal, 2001, 142, 952-959.	1.2	324
97	Pathway analysis of seven common diseases assessed by genome-wide association. Genomics, 2008, 92, 265-272.	1.3	324
98	Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United States. New England Journal of Medicine, 1994, 331, 1130-1135.	13.9	322
99	Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Î²3 Blockade With Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 1997, 278, 479.	3.8	317
100	Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet, The, 1999, 354, 2019-2024.	6.3	316
101	Wearable sensor data and self-reported symptoms for COVID-19 detection. Nature Medicine, 2021, 27, 73-77.	15.2	316
102	Predictors and Impact of Major Hemorrhage on Mortality Following Percutaneous Coronary Intervention from the REPLACE-2 Trial. American Journal of Cardiology, 2007, 100, 1364-1369.	0.7	315
103	Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. Journal of the American College of Cardiology, 2002, 39, 9-14.	1.2	313
104	Troponin T Levels in Patients with Acute Coronary Syndromes, with or without Renal Dysfunction. New England Journal of Medicine, 2002, 346, 2047-2052.	13.9	313
105	Abciximab reduces mortality in diabetics following percutaneous coronary intervention. Journal of the American College of Cardiology, 2000, 35, 922-928.	1.2	312
106	Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy. Journal of the American College of Cardiology, 1993, 22, 381-389.	1.2	308
107	Significance of Mild Transient Release of Creatine Kinaseâ€“MB Fraction After Percutaneous Coronary Interventions. Circulation, 1996, 94, 1528-1536.	1.6	305
108	Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. American Journal of Cardiology, 2005, 95, 1218-1222.	0.7	304

#	Article	IF	Citations
109	Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet, The, 2001, 357, 1063-1068.	6.3	293
110	Patients with peripheral arterial disease in the CHARISMA trial. European Heart Journal, 2008, 30, 192-201.	1.0	290
111	The importance of phase information for human genomics. Nature Reviews Genetics, 2011, 12, 215-223.	7.7	288
112	Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal, 2006, 27, 647-654.	1.0	286
113	Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Nonâ€“ST-Elevation Acute Coronary Syndromes. Circulation, 1999, 100, 2045-2048.	1.6	281
114	Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. Journal of the American College of Cardiology, 1993, 21, 1539-1549.	1.2	274
115	Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. Journal of the American College of Cardiology, 1993, 21, 920-925.	1.2	273
116	Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus. Circulation, 1999, 100, 2477-2484.	1.6	272
117	Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction. Circulation, 2001, 104, 2641-2644.	1.6	272
118	Angiographic Findings and Outcome in Diabetic Patients Treated With Thrombolytic Therapy for Acute Myocardial Infarction: The GUSTO-I Experience. Journal of the American College of Cardiology, 1996, 28, 1661-1669.	1.2	270
119	Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery. Circulation, 2001, 103, 363-368.	1.6	266
120	Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. American Journal of Cardiology, 1992, 69, 63-68.	0.7	262
121	Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist. Nature Medicine, 2020, 26, 1320-1324.	15.2	262
122	Value of Serial Troponin T Measures for Early and Late Risk Stratification in Patients With Acute Coronary Syndromes. Circulation, 1998, 98, 1853-1859.	1.6	259
123	Lack of Adverse Clopidogrelâ€“Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial. Circulation, 2003, 108, 921-924.	1.6	259
124	Sustained Local Delivery of Dexamethasone by a Novel Intravascular Eluting Stent to Prevent Restenosis in the Porcine Coronary Injury Model. Journal of the American College of Cardiology, 1997, 29, 808-816.	1.2	252
125	Toward a New Frontier in Myocardial Reperfusion Therapy. Circulation, 1998, 97, 211-218.	1.6	248
126	Individualized Medicine from Prewomb to Tomb. Cell, 2014, 157, 241-253.	13.5	247

#	Article	IF	Citations
127	Stroke After Thrombolysis. Circulation, 1995, 92, 2811-2818.	1.6	244
128	Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention. Circulation, 2001, 104, 992-997.	1.6	241
129	Propensity Analysis of Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease and High-Risk Features. Circulation, 2004, 109, 2290-2295.	1.6	240
130	Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention. Circulation, 1995, 91, 2151-2157.	1.6	238
131	Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention. Circulation, 2002, 105, 691-696.	1.6	237
132	Acute Coronary Syndromes in the GUSTO-IIb Trial. Circulation, 1998, 98, 1860-1868.	1.6	235
133	Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction. Circulation, 1996, 93, 870-878.	1.6	232
134	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 2012, 91, 823-838.	2.6	227
135	Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome. Journal of the American College of Cardiology, 2003, 41, 916-924.	1.2	226
136	Cardiogenic Shock in Patients With Acute Ischemic Syndromes With and Without ST-Segment Elevation. Circulation, 1999, 100, 2067-2073.	1.6	225
137	Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction. Journal of Experimental Medicine, 2003, 197, 615-624.	4.2	224
138	Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the USA: a population-based study. The Lancet Digital Health, 2020, 2, e85-e93.	5.9	224
139	Age and Outcome With Contemporary Thrombolytic Therapy. Circulation, 1996, 94, 1826-1833.	1.6	224
140	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2010, 376, 517-523.	6.3	222
141	Experimental models of coronary artery restenosis. Journal of the American College of Cardiology, 1992, 19, 418-432.	1.2	219
142	Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. Circulation, 2010, 121, 2575-2583.	1.6	218
143	Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 1995, 91, 2882-2890.	1.6	216
144	Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (P Journal of Cardiology, 2004, 93, 1092-1096.	0.7	215

#	Article	IF	Citations
145	Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. Journal of the American College of Cardiology, 1999, 33, 88-96.	1.2	212
146	Effects of a 5-Lipoxygenaseâ€“Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 2245.	3.8	212
147	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. Circulation, 2008, 118, 1705-1712.	1.6	210
148	Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. American Journal of Cardiology, 1995, 76, 1222-1227.	0.7	209
149	Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Mechanism of the â€œsmoker's paradoxâ€•from the GUSTO-I trial, with angiographic insights. Journal of the American College of Cardiology, 1995, 26, 1222-1229.	1.2	209
150	Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin Tâ€“Positive Status. Circulation, 2001, 103, 2891-2896.	1.6	206
151	Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. American Journal of Cardiology, 1996, 77, 1045-1051.	0.7	205
152	Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease. Circulation, 2003, 108, 399-406.	1.6	205
153	Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study was supported by Centocor, Inc., Malvern, Pennsylvania.. Journal of the American College of Cardiology, 1997, 30, 149-156.	1.2	204
154	Death Following Creatine Kinase-MB Elevation After Coronary Intervention. Circulation, 2002, 106, 1205-1210.	1.6	204
155	Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts. Circulation, 2002, 106, 3063-3067.	1.6	201
156	Heparin-Induced Thrombocytopenia. Journal of the American College of Cardiology, 1998, 31, 1449-1459.	1.2	198
157	Frontiers in Interventional Cardiology. Circulation, 1998, 98, 1802-1820.	1.6	198
158	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
159	Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization. Circulation, 2001, 104, 163-167.	1.6	197
160	New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience. American Heart Journal, 2000, 140, 878-885.	1.2	195
161	Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions. Circulation, 2003, 107, 1750-1756.	1.6	195
162	Prognostic Importance of Physical Examination for Heart Failure in Nonâ€“ST-Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2003, 290, 2174.	3.8	195

#	Article	IF	Citations
163	Premature Myocardial Infarction Novel Susceptibility Locus on Chromosome 1P34-36 Identified by Genomewide Linkage Analysis. American Journal of Human Genetics, 2004, 74, 262-271.	2.6	195
164	Sustained Ventricular Arrhythmias in Patients Receiving Thrombolytic Therapy. Circulation, 1998, 98, 2567-2573.	1.6	194
165	Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction. Circulation, 1997, 95, 2508-2516.	1.6	194
166	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2004, 148, 263-268.	1.2	193
167	A Randomized Controlled Trial of Hospital Discharge Three Days after Myocardial Infarction in the Era of Reperfusion. New England Journal of Medicine, 1988, 318, 1083-1088.	13.9	191
168	Outmigration For Coronary Bypass Surgery in an Era of Public Dissemination of Clinical Outcomes. Circulation, 1996, 93, 27-33.	1.6	191
169	Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events. Stroke, 2004, 35, 528-532.	1.0	190
170	Whole-Genome Sequencing of a Healthy Aging Cohort. Cell, 2016, 165, 1002-1011.	13.5	190
171	Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease. Circulation, 2000, 102, 1101-1106.	1.6	188
172	Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Journal of the American College of Cardiology, 2000, 35, 1103-1115.	1.2	184
173	Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction. Journal of the American College of Cardiology, 2000, 36, 1489-1496.	1.2	178
174	Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2006, 47, 939-943.	1.2	177
175	Impact of an Aggressive Invasive Catheterization and Revascularization Strategy on Mortality in Patients With Cardiogenic Shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation, 1997, 96, 122-127.	1.6	177
176	Thrombosis of a flexible coil coronary stent: Frequency, predictors and clinical outcome. Journal of the American College of Cardiology, 1993, 21, 622-627.	1.2	175
177	Use of Intraaortic Balloon Counterpulsation in Patients Presenting With Cardiogenic Shock: Observations From the GUSTO-I Study fn1fn1This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1997, 30, 708-715.	1.2	175
178	Intensive Statin Therapy â€" A Sea Change in Cardiovascular Prevention. New England Journal of Medicine, 2004, 350, 1562-1564.	13.9	175
179	The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. American Heart Journal, 2008, 155, 687-693.	1.2	175
180	Cardiogenic shock complicating acute myocardial infarction: Predictors of death. American Heart Journal, 1999, 138, 21-31.	1.2	173

#	Article	IF	Citations
181	Impact of body mass index on outcome after percutaneous coronary intervention (the obesity) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	173
182	Prognostic significance of elevated troponin i after percutaneous coronary intervention. Journal of the American College of Cardiology, 2002, 39, 1738-1744.	1.2	170
183	Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). American Heart Journal, 2002, 143, 847-853.	1.2	169
184	A Multicenter, Randomized Trial of Coronary Angioplasty Versus Directional Atherectomy for Patients With Saphenous Vein Bypass Graft Lesions. Circulation, 1995, 91, 1966-1974.	1.6	169
185	Cardiogenic shock complicating acute coronary syndromes. Lancet, The, 2000, 356, 749-756.	6.3	168
186	Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury. Circulation, 2003, 107, 2238-2243.	1.6	168
187	High-Definition Medicine. Cell, 2017, 170, 828-843.	13.5	168
188	Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. American Journal of Medicine, 1988, 85, 353-359.	0.6	164
189	Determinants of the Use of Coronary Angiography and Revascularization after Thrombolysis for Acute Myocardial Infarction. New England Journal of Medicine, 1996, 335, 1198-1205.	13.9	164
190	Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. Journal of the American College of Cardiology, 2002, 40, 1961-1967.	1.2	163
191	Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications. Circulation, 2004, 110, 994-998.	1.6	163
192	Myeloperoxidase-Generated Oxidants Modulate Left Ventricular Remodeling but Not Infarct Size After Myocardial Infarction. Circulation, 2005, 112, 2812-2820.	1.6	163
193	With an eye to AI and autonomous diagnosis. Npj Digital Medicine, 2018, 1, 40.	5.7	163
194	Lack of Evidence of a Clopidogrelâ€“Statin Interaction in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 50, 291-295.	1.2	162
195	Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. Annals of Internal Medicine, 2010, 153, 425.	2.0	161
196	Effect of Cigarette Smoking on Outcome After Thrombolytic Therapy for Myocardial Infarction. Circulation, 1995, 91, 298-303.	1.6	161
197	Initial report of the National Registry of Elective Cardiopulmonary bypass supported coronary angioplasty. Journal of the American College of Cardiology, 1990, 15, 23-29.	1.2	157
198	Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction Treatment. Journal of the American College of Cardiology, 1998, 31, 1466-1473.	1.2	157

#	Article	IF	Citations
199	Platelet Glycoprotein IIb/IIIa Inhibitors. Circulation, 2002, 106, 379-385.	1.6	157
200	Effect of age on outcome with primary angioplasty versus thrombolysis. Journal of the American College of Cardiology, 1999, 33, 412-419.	1.2	156
201	Novel Wireless Devices for Cardiac Monitoring. Circulation, 2014, 130, 573-581.	1.6	156
202	Prediction of infarct coronary artery recanalization after intravenous thrombolytic therapy. American Journal of Cardiology, 1987, 59, 513-515.	0.7	155
203	Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab. Circulation, 1999, 99, 1951-1958.	1.6	154
204	Multicenter study of percutaneous transluminal angioplasty for right coronary artery ostial stenosis. Journal of the American College of Cardiology, 1987, 9, 1214-1218.	1.2	152
205	The Influence of Peripheral Arterial Disease on Outcomes. Journal of the American College of Cardiology, 2006, 48, 1567-1572.	1.2	152
206	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. Annals of Internal Medicine, 2009, 150, 379.	2.0	152
207	Genetic susceptibility to myocardial infarction and coronary artery disease. Human Molecular Genetics, 2006, 15, R117-R123.	1.4	151
208	From myocardial salvage to patient salvage in acute myocardial infarction: The role of reperfusion therapy. Journal of the American College of Cardiology, 1989, 14, 1382-1388.	1.2	149
209	Vascular Access Site Complications After Percutaneous Coronary Intervention With Abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Trial. American Journal of Cardiology, 1998, 81, 36-40.	0.7	148
210	Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). American Journal of Cardiology, 1995, 75, 559-562.	0.7	147
211	Clinical Significance of Thrombocytopenia During a Nonâ€“ST-Elevation Acute Coronary Syndrome. Circulation, 1999, 99, 2892-2900.	1.6	146
212	Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics, 2005, 6, 58.	1.2	146
213	Thrombolytic Therapy for Acute Myocardial Infarction. Drugs, 1992, 44, 293-325.	4.9	145
214	Extended Mortality Benefit of Early Postinfarction Reperfusion. Circulation, 1998, 97, 1549-1556.	1.6	145
215	Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb11Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON-A); Global Use of Strategies To Open occluded arteries in acute coronary syndromes (GUSTO-IIb).. Journal of the American College of Cardiology, 2001, 38, 64-71.	1.2	145
216	Influence of Blockade at Specific Levels of the Coagulation Cascade on Restenosis in a Rabbit Atherosclerotic Femoral Artery Injury Model. Circulation, 1995, 92, 3041-3050.	1.6	145

#	Article	IF	Citations
217	Effect of Clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. American Journal of Cardiology, 2001, 88, 672-674.	0.7	144
218	A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2030-2036.	1.1	143
219	Is Pocket Mobile Echocardiography the Next-Generation Stethoscope? A Cross-sectional Comparison of Rapidly Acquired Images With Standard Transthoracic Echocardiography. Annals of Internal Medicine, 2011, 155, 33.	2.0	143
220	Identification of Four Gene Variants Associated with Myocardial Infarction. American Journal of Human Genetics, 2005, 77, 596-605.	2.6	142
221	Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Journal of the American College of Cardiology, 1998, 32, 311-319.	1.2	141
222	Gender and Acute Myocardial Infarction: Is There a Different Response to Thrombolysis?. Journal of the American College of Cardiology, 1997, 29, 35-42.	1.2	140
223	Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Journal of the American College of Cardiology, 1998, 32, 634-640.	1.2	139
224	Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation. Circulation, 2002, 106, 309-312.	1.6	139
225	Unpatientsâ€"why patients should own their medical data. Nature Biotechnology, 2015, 33, 921-924.	9.4	138
226	Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT). Journal of the American College of Cardiology, 1995, 25, 1693-1699.	1.2	137
227	Standard Versus Low-Dose Weight-Adjusted Heparin in Patients Treated With the Platelet Glycoprotein IIb/IIIa Receptor Antibody Fragment Abciximab (c7E3 Fab) During Percutaneous Coronary Revascularization. American Journal of Cardiology, 1997, 79, 286-291.	0.7	137
228	Need to Test the Arterial Inflammation Hypothesis. Circulation, 2002, 106, 136-140.	1.6	137
229	Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology, 2001, 37, 2059-2065.	1.2	136
230	Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. Journal of the American College of Cardiology, 1991, 18, 1077-1084.	1.2	135
231	Acute Myocardial Infarction and Complete Bundle Branch Block at Hospital Admission: Clinical Characteristics and Outcome in the Thrombolytic Era fn1fn1This study was supported by grants from Bayer Corporation, New York, New York; Genentech, Inc., South San Francisco, California; CIBA-Corning, Medford, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1998, 31, 105-110.	1.2	135
232	Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender. Journal of the American College of Cardiology, 2000, 36, 381-386.	1.2	134
233	Increased Expression of Thrombospondin-1 in Vessel Wall of Diabetic Zucker Rat. Circulation, 2003, 107, 3209-3215.	1.6	134
234	Risk factors and outcomes in patients with ventricular septal defects (VSD) complicating acute MI. Journal of the American College of Cardiology, 1996, 27, 67-68.	1.2	133

#	Article	IF	Citations
235	Prediction of 1-Year Survival After Thrombolysis for Acute Myocardial Infarction in the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation, 2000, 101, 2231-2238.	1.6	133
236	Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. American Heart Journal, 2000, 140, 67-73.	1.2	133
237	Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. American Journal of Cardiology, 1999, 84, 1281-1286.	0.7	132
238	Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association With Clinical Outcome in Patients Undergoing Coronary Stenting. Circulation, 2004, 109, 2203-2206.	1.6	132
239	Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 2000, 35, 136-143.	1.2	130
240	Periprocedural Cardiac Enzyme Elevation Predicts Adverse Outcomes. Circulation, 2005, 112, 906-922.	1.6	129
241	Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. Journal of the American College of Cardiology, 1990, 16, 770-778.	1.2	128
242	Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty. A matched case-control study. Journal of the American College of Cardiology, 1993, 21, 866-875.	1.2	128
243	Cost Effectiveness of Early Discharge after Uncomplicated Acute Myocardial Infarction. New England Journal of Medicine, 2000, 342, 749-755.	13.9	127
244	Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 1928-1937.	1.2	127
245	Longitudinal Genome-Wide Association of Cardiovascular Disease Risk Factors in the Bogalusa Heart Study. PLoS Genetics, 2010, 6, e1001094.	1.5	126
246	Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2002, 288, 2130.	3.8	125
247	Impact of direct-to-consumer genomic testing at long term follow-up. Journal of Medical Genetics, 2013, 50, 393-400.	1.5	125
248	Digital Medical Tools and Sensors. JAMA - Journal of the American Medical Association, 2015, 313, 353.	3.8	125
249	Cardiogenic shock complicating acute myocardial infarction: The use of coronary angioplasty and the integration of the new support devices into patient management. Journal of the American College of Cardiology, 1992, 19, 647-653.	1.2	124
250	Cardiac rupture associated with thrombolytic therapy: Impact of time to treatment in the late assessment of thrombolytic efficacy (LATE) study. Journal of the American College of Cardiology, 1995, 25, 1063-1068.	1.2	124
251	Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. Journal of the American College of Cardiology, 2000, 36, 685-692.	1.2	124
252	The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 621-635.	3.3	123

#	Article	IF	Citations
253	Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease. Circulation, 2009, 120, 2337-2344.	1.6	123
254	Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiological Genomics, 2003, 13, 25-30.	1.0	122
255	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 2011, 88, 6-18.	2.6	122
256	Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. Journal of the American College of Cardiology, 1998, 32, 1619-1623.	1.2	121
257	Prior aspirin use predicts worse outcomes in patients with nonâ€“ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey.. American Journal of Cardiology, 1999, 83, 1147-1151.	0.7	121
258	Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. American Journal of Cardiology, 1997, 80, 985-988.	0.7	119
259	The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology, 2009, 54, 1935-1945.	1.2	119
260	Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty. Circulation, 1996, 94, 629-635.	1.6	119
261	Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) trial. Journal of the American College of Cardiology, 1996, 27, 625-632.	1.2	117
262	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 2004, 93, 679-684.	0.7	117
263	Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Medical Genomics, 2011, 4, 26.	0.7	117
264	Nesiritide â€" Not Verified. New England Journal of Medicine, 2005, 353, 113-116.	13.9	116
265	Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2005, 46, 761-769.	1.2	115
266	Strategies to achieve coronary arterial plaque stabilization. Cardiovascular Research, 1999, 41, 402-417.	1.8	114
267	Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. Annals of Emergency Medicine, 2002, 39, 123-130.	0.3	113
268	Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radical Biology and Medicine, 2006, 41, 1678-1683.	1.3	113
269	Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events. Circulation, 2001, 103, 1403-1409.	1.6	112
270	Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary interventionResults from the REPLACE-2 trial. Journal of the American College of Cardiology, 2004, 44, 1792-1800.	1.2	112

#	Article	IF	Citations
271	A robust hybrid between genetic algorithm and support vector machine for extracting an optimal feature gene subset. Genomics, 2005, 85, 16-23.	1.3	112
272	The Myth of the Myocardial â€˜Infarctletâ€™ During Percutaneous Coronary Revascularization Procedures. Circulation, 1996, 94, 3369-3375.	1.6	112
273	Effects of Antisense c- myb Oligonucleotides on Vascular Smooth Muscle Cell Proliferation and Response to Vessel Wall Injury. Circulation Research, 1995, 76, 505-513.	2.0	112
274	Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization11The names and institutions participating in these trials are provided in the appendices of references 1 to 3.. American Journal of Medicine, 2002, 113, 1-6.	0.6	111
275	Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival. Journal of the American College of Cardiology, 2003, 42, 1188-1195.	1.2	111
276	Long-Term Outcome and its Predictors Among Patients With ST-Segment Elevation Myocardial Infarction Complicated by Shock. Journal of the American College of Cardiology, 2007, 50, 1752-1758.	1.2	110
277	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. American Heart Journal, 2009, 157, 818-824.e1.	1.2	110
278	Scorecard Cardiovascular Medicine: Its Impact and Future Directions. Annals of Internal Medicine, 1994, 120, 65.	2.0	109
279	Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. Journal of the American College of Cardiology, 2000, 36, 75-83.	1.2	109
280	Meta-Analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. Journal of the American College of Cardiology, 2004, 43, 936-942.	1.2	109
281	Gainâ€ofâ€function ADCY5 mutations in familial dyskinesia with facial myokymia. Annals of Neurology, 2014, 75, 542-549.	2.8	109
282	Thrombolytic therapy for women with myocardial infarction: Is there a gender gap?. Journal of the American College of Cardiology, 1993, 22, 1780-1787.	1.2	108
283	Role of Platelets in Restenosis After Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 1996, 28, 1643-1651.	1.2	108
284	In Unstable Angina or Nonâ€“ST-Segment Acute Coronary Syndrome, Should Patients With Multivessel Coronary Artery Disease Undergo Multivessel or Culprit-Only Stenting?. Journal of the American College of Cardiology, 2007, 49, 849-854.	1.2	108
285	A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15483-15488.	3.3	108
286	The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. American Heart Journal, 1991, 121, 895-901.	1.2	107
287	Neointimal Hyperplasia After Arterial Injury Is Increased in a Rat Model of Nonâ€“Insulin-Dependent Diabetes Mellitus. Circulation, 2001, 104, 815-819.	1.6	107
288	Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 2009, 103, 1359-1363.	0.7	107

#	Article	IF	Citations
289	Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genetics in Medicine, 2010, 12, 556-566.	1.1	107
290	Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Circulation, 1999, 100, 1977-1982.	1.6	106
291	Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Nonâ€“ST-Elevation Acute Coronary Syndromes. Circulation, 2000, 101, 366-371.	1.6	106
292	Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. American Heart Journal, 2009, 157, 658-665.	1.2	106
293	Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. American Journal of Cardiology, 1994, 74, 1166-1170.	0.7	105
294	Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). Journal of the American College of Cardiology, 1995, 26, 922-930.	1.2	105
295	Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. American Journal of Cardiology, 2002, 89, 132-136.	0.7	105
296	Thrombospondin-4 and Its Variants. Circulation, 2003, 108, 1514-1519.	1.6	105
297	Protective alleles and modifier variants in human health and disease. Nature Reviews Genetics, 2015, 16, 689-701.	7.7	105
298	Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes. Circulation, 2000, 101, 751-757.	1.6	104
299	Arthritis Medicines and Cardiovascular Eventsâ€”â€œHouse of Coxibsâ€• JAMA - Journal of the American Medical Association, 2005, 293, 366.	3.8	104
300	Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biology, 2009, 10, R116.	13.9	104
301	Aspirin resistance and a single gene. American Journal of Cardiology, 2005, 95, 805-808.	0.7	103
302	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 2010, 31, 35-49.	1.0	103
303	Inter- and intraindividual variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time of year: Retrospective, longitudinal cohort study of 92,457 adults. PLoS ONE, 2020, 15, e0227709.	1.1	103
304	Clinical Outcomes of Bivalirudin for Ischemic Heart Disease. Circulation, 1999, 100, 2049-2053.	1.6	101
305	Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. Journal of the American College of Cardiology, 2002, 39, 377-386.	1.2	101
306	Thrombospondinâ€1 upâ€regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB Journal, 2005, 19, 1158-1160.	0.2	101

#	Article	IF	Citations
307	Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke, 2012, 43, 1058-1066.	1.0	101
308	One-Year Follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). Circulation, 1995, 91, 2158-2166.	1.6	101
309	Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1989, 14, 877-884.	1.2	100
310	Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. American Journal of Cardiology, 2004, 94, 358-360.	0.7	100
311	Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Research, 2010, 20, 537-545.	2.4	100
312	Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. American Journal of Cardiology, 2003, 92, 651-655.	0.7	97
313	Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials. American Heart Journal, 2003, 145, 73-79.	1.2	97
314	Coronary-Artery Stents â€" Gauging, Gorging, and Gouging. New England Journal of Medicine, 1998, 339, 1702-1704.	13.9	96
315	Predictors and Sequelae of Distal Embolization During Saphenous Vein Graft Intervention From the CAVEAT-II Trial. Circulation, 1995, 92, 734-740.	1.6	96
316	First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade. Circulation, 1997, 96, 76-81.	1.6	96
317	Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet, The, 1997, 349, 75-78.	6.3	95
318	Unveiling the Role of the Most Impactful Cardiovascular Risk Locus through Haplotype Editing. Cell, 2018, 175, 1796-1810.e20.	13.5	95
319	COVID-19 can affect the heart. Science, 2020, 370, 408-409.	6.0	95
320	Early Reinfarction After Fibrinolysis. Circulation, 2001, 104, 1229-1235.	1.6	94
321	Regionalization of Care for Acute Ischemic Heart Disease. Circulation, 2003, 107, 1463-1466.	1.6	94
322	Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. American Heart Journal, 2005, 149, 670-674.	1.2	94
323	Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. American Journal of Cardiology, 1991, 67, 225-230.	0.7	93
324	Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. American Journal of Cardiology, 2000, 86, 780-782.	0.7	93

#	Article	IF	Citations
325	Transcription factor MEF2A mutations in patients with coronary artery disease. Human Molecular Genetics, 2004, 13, 3181-3188.	1.4	93
326	Randomized Comparison of Direct Thrombin Inhibition Versus Heparin in Conjunction With Fibrinolytic Therapy for Acute Myocardial Infarction: Results From the GUSTO-IIb Trial. Journal of the American College of Cardiology, 1998, 31, 1493-1498.	1.2	92
327	Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban. Circulation, 1998, 98, 1268-1278.	1.6	92
328	Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. European Heart Journal, 2006, 27, 413-418.	1.0	92
329	Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: Influence of infarct location on arterial patency, left ventricular function and mortality. Journal of the American College of Cardiology, 1989, 13, 12-18.	1.2	91
330	A Call for Provisional Stenting. Circulation, 1998, 97, 1298-1305.	1.6	91
331	One-Year Survival Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock, and its Relation to Early Revascularization. Circulation, 1999, 99, 873-878.	1.6	91
332	Pharmacogenomics in clinical practice and drug development. Nature Biotechnology, 2012, 30, 1117-1124.	9.4	91
333	One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation, 1996, 94, 1233-1238.	1.6	91
334	Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. American Heart Journal, 1996, 131, 1097-1105.	1.2	90
335	Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: Development of a predictive model. American Heart Journal, 1997, 133, 663-673.	1.2	90
336	Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Human Genetics, 2003, 114, 87-98.	1.8	90
337	Peroxisome Proliferator-Activated Receptor Î³ Down-Regulates Receptor for Advanced Glycation End Products and Inhibits Smooth Muscle Cell Proliferation in a Diabetic and Nondiabetic Rat Carotid Artery Injury Model. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 37-43.	1.3	90
338	Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). American Journal of Cardiology, 2005, 95, 581-585.	0.7	89
339	Relation Between Lesion Characteristics and Risk With Percutaneous Intervention in the Stent and Glycoprotein IIb/IIIa Era. Circulation, 1999, 100, 1971-1976.	1.6	88
340	Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. American Heart Journal, 2004, 147, 684.	1.2	88
341	A coxib a day won't keep the doctor away. Lancet, The, 2004, 364, 639-640.	6.3	88
342	Late Myocardial Ischemic Events After Saphenous Vein Graft Interventionâ€"Importance of Initially â€œNonsignificantâ€•Vein Graft Lesions. American Journal of Cardiology, 1997, 79, 1460-1464.	0.7	87

#	Article	IF	Citations
343	Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2002, 105, 2730-2736.	1.6	87
344	Significance of a coronary artery with Thrombolysis in Myocardial infarction grade 2 flow â€œpatencyâ€• (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction trials). American Journal of Cardiology, 1995, 75, 871-876.	0.7	86
345	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal, 2012, 33, 2143-2150.	1.0	86
346	Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. American Heart Journal, 1991, 122, 943-948.	1.2	85
347	A Covering Method for Detecting Genetic Associations between Rare Variants and Common Phenotypes. PLoS Computational Biology, 2010, 6, e1000954.	1.5	85
348	Direct-to-consumer personalized genomic testing. Human Molecular Genetics, 2011, 20, R132-R141.	1.4	84
349	Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: Improved timing, thrombolytic efficacy and ventricular function. Journal of the American College of Cardiology, 1987, 10, 1173-1177.	1.2	83
350	Caveats about Elective Coronary Stenting. New England Journal of Medicine, 1994, 331, 539-541.	13.9	83
351	Diabetic Retinopathy Should Not Be a Contraindication to Thrombolytic Therapy for Acute Myocardial Infarction: Review of Ocular Hemorrhage Incidence and Location in the GUSTO-I Trial fn1fn1This study was supported by Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France. Journal of the American College of Cardiology, 1997, 30, 1606-1610.	1.2	83
352	Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. American Heart Journal, 2000, 140, 74-80.	1.2	83
353	Clinical Trialsâ€”Multiple Treatments, Multiple End Points, and Multiple Lessons. JAMA - Journal of the American Medical Association, 2003, 289, 2575.	3.8	83
354	A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors. PeerJ, 2016, 4, e1554.	0.9	82
355	Abciximab Therapy and Unplanned Coronary Stent Deployment. Circulation, 1998, 97, 857-864.	1.6	81
356	A preferred reperfusion strategy for acute myocardial infarction**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2003, 42, 1886-1889.	1.2	81
357	Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. Journal of the American College of Cardiology, 1998, 31, 1518-1524.	1.2	80
358	Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Annals of Thoracic Surgery, 2000, 70, 516-526.	0.7	80
359	Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet, The, 2002, 360, 355-360.	6.3	80
360	Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. Journal of the American College of Cardiology, 2004, 43, 1908-1914.	1.2	80

#	Article	IF	Citations
361	Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. American Journal of Cardiology, 2001, 88, 124-128.	0.7	79
362	Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2004, 25, 190-198.	1.0	79
363	Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: Results in 16,521 patients. Journal of the American College of Cardiology, 1996, 28, 305-312.	1.2	78
364	Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 187.	1.5	78
365	Selection of thrombolytic therapy for individual patients: Development of a clinical model. American Heart Journal, 1997, 133, 630-639.	1.2	77
366	The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related nonâ€“Q-wave myocardial infarctions. Journal of the American College of Cardiology, 1998, 32, 1366-1370.	1.2	77
367	Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy. Journal of the American College of Cardiology, 2000, 35, 1502-1512.	1.2	77
368	An LRP8 Variant Is Associated with Familial and Premature Coronary Artery Disease and Myocardial Infarction. American Journal of Human Genetics, 2007, 81, 780-791.	2.6	77
369	Characterization of Circulating Endothelial Cells in Acute Myocardial Infarction. Science Translational Medicine, 2012, 4, 126ra33.	5.8	77
370	Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Medicine, 2014, 12, 37.	2.3	77
371	Identification of new genes differentially expressed in coronary artery disease by expression profiling. Physiological Genomics, 2003, 15, 65-74.	1.0	76
372	Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals. JACC: Cardiovascular Interventions, 2009, 2, 917-924.	1.1	76
373	Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Cardiology, 1999, 84, 779-784.	0.7	74
374	In-hospital costs associated with new percutaneous coronary devices. American Journal of Cardiology, 1991, 68, 879-885.	0.7	73
375	In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization. Archives of Internal Medicine, 2003, 163, 2576.	4.3	73
376	Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial. International Journal of Stroke, 2011, 6, 3-9.	2.9	73
377	Atherectomy of right coronary ostial stenoses: Initial and long-term results, technical features and histologic findings. American Journal of Cardiology, 1991, 67, 431-433.	0.7	72
378	Nonâ€“Q-Wave Versus Q-Wave Myocardial Infarction After Thrombolytic Therapy. Circulation, 1998, 97, 444-450.	1.6	72

#	Article	IF	Citations
379	Stroke in Patients With Acute Coronary Syndromes. Circulation, 1999, 99, 2371-2377.	1.6	72
380	Integrin Î±IIbÎ²3and Its Antagonism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 945-952.	1.1	72
381	A decade of digital medicine innovation. Science Translational Medicine, 2019, 11, .	5.8	72
382	Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. Journal of the American College of Cardiology, 1996, 28, 1111-1118.	1.2	71
383	Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. American Heart Journal, 2002, 143, 242-248.	1.2	71
384	Gene Variants of VAMP8 and HNRPUL1 Are Associated With Early-Onset Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1613-1618.	1.1	71
385	The Genomics Gold Rush. JAMA - Journal of the American Medical Association, 2007, 298, 218.	3.8	71
386	Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial. American Heart Journal, 2000, 139, 927-933.	1.2	70
387	Long-Term Mortality of Patients With Acute Myocardial Infarction in the United States and Canada. Circulation, 2004, 110, 1754-1760.	1.6	70
388	Implications for patient triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial infarction. Journal of the American College of Cardiology, 1989, 13, 1251-1259.	1.2	69
389	Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions. Circulation, 2000, 102, 28-34.	1.6	69
390	Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. Journal of the American College of Cardiology, 2000, 35, 563-568.	1.2	69
391	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal, 2009, 157, 369-374.	1.2	69
392	Causes and correlates of death after unsupported coronary angioplasty: Implications for use of angioplasty and advanced support techniques in high-risk settings. American Journal of Cardiology, 1991, 68, 1447-1451.	0.7	68
393	Accelerated plasminogen activator dose regimens for coronary thrombolysis. Journal of the American College of Cardiology, 1992, 19, 482-489.	1.2	68
394	Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Disease, 1993, 4, 167-176.	0.3	68
395	Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Journal of the American College of Cardiology, 1998, 32, 2023-2030.	1.2	68
396	Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. European Heart Journal, 2005, 26, 2106-2113.	1.0	68

#	Article	IF	Citations
397	An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal, 2007, 28, 2200-2207.	1.0	68
398	In-Hospital Cost of Percutaneous Coronary Revascularization. Circulation, 1995, 92, 741-747.	1.6	68
399	Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France. Journal of the American College of Cardiology, 1998, 31, 497-505.	1.2	67
400	Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. Journal of the American College of Cardiology, 2003, 41, 371-380.	1.2	67
401	Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. American Heart Journal, 2004, 147, 246-252.	1.2	67
402	Welcoming new guidelines for AI clinical research. Nature Medicine, 2020, 26, 1318-1320.	15.2	67
403	Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19 Infection. JAMA Network Open, 2021, 4, e2115959.	2.8	67
404	Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 180.	1.5	66
405	Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology. Circulation, 1996, 93, 431-439.	1.6	66
406	Insights derived from the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials. Journal of the American College of Cardiology, 1988, 12, A24-A31.	1.2	65
407	Cocaine-induced aortic dissection. American Heart Journal, 1996, 132, 1301-1304.	1.2	64
408	Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. American Journal of Cardiology, 1998, 82, 7-12.	0.7	64
409	Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting. Circulation, 2002, 105, 2347-2354.	1.6	64
410	International differences in evolution of early discharge after acute myocardial infarction. Lancet, The, 2004, 363, 511-517.	6.3	64
411	Meta-Analysis: Cardiovascular Events Associated with Nonsteroidal Anti-inflammatory Drugs. American Journal of Medicine, 2006, 119, 552-559.	0.6	64
412	Age and outcome after acute coronary syndromes without persistent ST-segment elevation. American Heart Journal, 2000, 139, 858-866.	1.2	63
413	Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: A substudy of the GUSTO-III trial. American Heart Journal, 2002, 144, 81-88.	1.2	63
414	Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. American Heart Journal, 2006, 152, 1051.e9-1051.e14.	1.2	63

#	Article	IF	Citations
415	Prospects for the use of antagonists to the platelet glycoprotein IIb/ IIIa receptor to prevent postangioplasty restenosis and thrombosis. Journal of the American College of Cardiology, 1991, 17, 89-95.	1.2	62
416	Impact of Female Sex on Death and Bleeding After Fibrinolytic Treatment of Myocardial Infarction in GUSTO V. Archives of Internal Medicine, 2007, 167, 2054.	4.3	62
417	Transforming Medicine via Digital Innovation. Science Translational Medicine, 2010, 2, 16cm4.	5.8	62
418	Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: Results from the GUSTO-III trial. American Heart Journal, 2003, 145, 515-521.	1.2	61
419	Impact of Blood Transfusion on Short- and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2009, 2, 46-53.	1.1	61
420	Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: Prediction of clinical outcome. American Heart Journal, 1988, 115, 1-7.	1.2	60
421	Increased Risk of Non-Q Wave Myocardial Infarction After Directional Atherectomy Is Platelet Dependent: Evidence From the EPIC Trial. Journal of the American College of Cardiology, 1996, 28, 849-855.	1.2	60
422	The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. Journal of the American College of Cardiology, 1999, 33, 1269-1277.	1.2	60
423	Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. American Journal of Medicine, 2000, 109, 371-377.	0.6	60
424	Blockade of the Platelet P2Y12Receptor by AR-C69931MX Sustains Coronary Artery Recanalization and Improves the Myocardial Tissue Perfusion in a Canine Thrombosis Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 357-362.	1.1	60
425	Long-term Outcome of Transient, Uncomplicated In-Laboratory Coronary Artery Closure. Circulation, 1995, 91, 2733-2741.	1.6	60
426	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. JACC: Cardiovascular Interventions, 2009, 2, 909-916.	1.1	59
427	Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty?. Journal of the American College of Cardiology, 1993, 22, 1289-1297.	1.2	58
428	Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction. Circulation, 2000, 102, 1761-1765.	1.6	58
429	Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1994, 23, 891-898.	1.2	57
430	Prophylactic lidocaine use in acute myocardial infarction: Incidence and outcomes from two international trials. American Heart Journal, 1999, 137, 799-805.	1.2	57
431	Autologous cell transplantation for the treatment of damaged myocardium. Progress in Cardiovascular Diseases, 2002, 45, 21-32.	1.6	57
432	Differences in the Clinical Features and Outcomes in African Americans and Whites with Myocardial Infarction. American Journal of Medicine, 2006, 119, 70.e1-70.e8.	0.6	57

#	Article	IF	Citations
433	Future Use of Genomics in Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1933-1940.	1.2	57
434	A Whole Blood Molecular Signature for Acute Myocardial Infarction. Scientific Reports, 2017, 7, 12268.	1.6	57
435	Reduction in Myocardial Infarct Size by Basic Fibroblast Growth Factor After Temporary Coronary Occlusion in a Canine Model. Circulation, 1996, 94, 1927-1933.	1.6	57
436	Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. American Journal of Cardiology, 1999, 83, 482-487.	0.7	56
437	Enhanced Efficacy of Eptifibatide Administration in Patients With Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting. Circulation, 2000, 102, 2952-2958.	1.6	56
438	Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients â‰40 years old. American Journal of Cardiology, 2003, 92, 1465-1467.	0.7	56
439	Relationship Between Patientâ€™s Risk Profile and Benefits in Mortality From Adjunctive Abciximab to Mechanical Revascularization for ST-Segment Elevation Myocardial Infarction: A Meta-Regression Analysis of Randomized Trials. Journal of the American College of Cardiology, 2006, 47, 685-686.	1.2	56
440	Impact of Diabetes Mellitus on Percutaneous Revascularization (CAVEAT-I). American Journal of Cardiology, 1997, 79, 748-755.	0.7	55
441	Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention. Journal of the American College of Cardiology, 2004, 44, 1792-1800.	1.2	55
442	Coronary Angiography after Thrombolytic Therapy for Acute Myocardial Infarction. Annals of Internal Medicine, 1991, 114, 877-885.	2.0	54
443	Aspirin dose and six-month outcome after an acute coronary syndrome. Journal of the American College of Cardiology, 2004, 43, 972-978.	1.2	54
444	Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. American Heart Journal, 2004, 147, 905-909.	1.2	54
445	Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases. Genome Medicine, 2019, 11, 83.	3.6	54
446	Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. American Heart Journal, 1998, 136, 398-405.	1.2	53
447	Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial. Circulation, 2000, 102, 1375-1381.	1.6	53
448	Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting. Circulation, 2002, 105, 322-327.	1.6	53
449	Preprocedural white blood cell count and death after percutaneous coronary intervention. American Heart Journal, 2003, 146, 692-698.	1.2	53
450	Mortality Benefit of Beta Blockade in Patients with Acute Coronary Syndromes Undergoing Coronary Intervention:. Journal of Interventional Cardiology, 2003, 16, 299-305.	0.5	52

#	Article	IF	Citations
451	The Genomic Basis of Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 1456-1465.	1.2	52
452	Moving From Digitalization to Digitization in Cardiovascular Care. Journal of the American College of Cardiology, 2015, 66, 1489-1496.	1.2	52
453	Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial. American Heart Journal, 2016, 175, 77-85.	1.2	52
454	Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. Journal of the American College of Cardiology, 2001, 38, 577-582.	1.2	51
455	Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction. Thrombosis and Haemostasis, 1991, 65, 275-279.	1.8	51
456	Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Journal of the American College of Cardiology, 1992, 19, 1123-1128.	1.2	50
457	Significance of Atrial Fibrillation During Acute Myocardial Infarction, and its Current Management: Insights from the GUSTO-3 Trial. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 201-207.	0.9	50
458	Thrombospondins, Their Polymorphisms, and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1886-1894.	1.1	50
459	The Unmet Need of Education in Genomic Medicine. American Journal of Medicine, 2012, 125, 5-6.	0.6	50
460	Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics, 2001, 2, 341-352.	0.6	49
461	Role of stem cell homing in myocardial regeneration. International Journal of Cardiology, 2004, 95, S23-S25.	0.8	49
462	Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function. Blood, 2005, 106, 3970-3978.	0.6	49
463	Clinical Trials of Platelet Receptor Inhibitors. Thrombosis and Haemostasis, 1993, 70, 094-098.	1.8	49
464	Prediction of 30-Day Mortality Among Patients With Thrombolysis-Related Intracranial Hemorrhage. Circulation, 1998, 98, 1376-1382.	1.6	48
465	Redefining medical treatment in the management of unstable angina. American Journal of Medicine, 2000, 108, 41-53.	0.6	48
466	The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal, 2005, 149, 869-875.	1.2	48
467	The genetics of health. Nature Genetics, 2006, 38, 1095-1098.	9.4	48
468	Genomic information as a behavioral health intervention: can it work?. Personalized Medicine, 2011, 8, 659-667.	0.8	48

#	Article	IF	Citations
469	Passive detection of COVID-19 with wearable sensors and explainable machine learning algorithms. Npj Digital Medicine, 2021, 4, 166.	5.7	48
470	Smartphone apps in the COVID-19 pandemic. Nature Biotechnology, 2022, 40, 1013-1022.	9.4	48
471	Predictors of success for coronary angioplasty performed for acute myocardial infarction. Journal of the American College of Cardiology, 1988, 12, 1407-1415.	1.2	47
472	Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicenter Trial fn1fn1This study was suppported by a grant from Centocor, Inc.. Journal of the American College of Cardiology, 1998, 31, 31-36.	1.2	47
473	The resequencing imperative. Nature Genetics, 2007, 39, 439-440.	9.4	47
474	Emergency percutaneous transluminal coronary angioplasty during acute myocardial infarction for patients more than 70 years of age. American Journal of Cardiology, 1989, 63, 399-403.	0.7	46
475	Coronary artery disease and the thrombospondin single nucleotide polymorphisms. International Journal of Biochemistry and Cell Biology, 2004, 36, 1013-1030.	1.2	46
476	Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease. Stroke, 2006, 37, 1427-1431.	1.0	45
477	The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. European Heart Journal, 2007, 28, 415-424.	1.0	45
478	The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal, 2008, 30, 857-865.	1.0	45
479	iMedEd. Academic Medicine, 2014, 89, 1207-1209.	0.8	45
480	Atrioventricular and Intraventricular Conduction Disorders in Acute Myocardial Infarction: A Reappraisal in the Thrombolytic Era. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2651-2663.	0.5	44
481	Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I Trial. American Heart Journal, 1999, 138, 493-499.	1.2	44
482	Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). American Heart Journal, 2002, 144, 995-1002.	1.2	44
483	Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. American Heart Journal, 2004, 147, 31-34.	1.2	44
484	The Case for Routine Genotyping in Dual-Antiplatelet Therapy. Journal of the American College of Cardiology, 2010, 56, 109-111.	1.2	44
485	Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials. Journal of the American Heart Association, 2013, 2, e004564.	1.6	44
486	Messenger RNA vaccines against SARS-CoV-2. Cell, 2021, 184, 1401.	13.5	44

#	Article	IF	Citations
487	Adjunctive Selectin Blockade Successfully Reduces Infarct Size Beyond Thrombolysis in the Electrolytic Canine Coronary Artery Model. Circulation, 1995, 92, 492-499.	1.6	44
488	Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogeh activator therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1988, 11, 899-907.	1.2	43
489	Novel antithrombotic approaches to coronary artery disease. American Journal of Cardiology, 1995, 75, 27B-33B.	0.7	43
490	Restenosisâ€"an open file. Clinical Cardiology, 1996, 19, 347-356.	0.7	43
491	The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. Journal of the American College of Cardiology, 2002, 39, 22-29.	1.2	43
492	Abrupt vessel closure after directional coronary atherectomy. Journal of the American College of Cardiology, 1992, 19, 1372-1379.	1.2	42
493	Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Molecular Therapy, 2003, 7, 597-603.	3.7	42
494	Molecular and Functional Differences Induced in Thrombospondin-1 by the Single Nucleotide Polymorphism Associated with the Risk of Premature, Familial Myocardial Infarction. Journal of Biological Chemistry, 2004, 279, 21651-21657.	1.6	42
495	Molecular Autopsy for Sudden Unexpected Death. JAMA - Journal of the American Medical Association, 2016, 316, 1492.	3.8	42
496	Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy. American Journal of Cardiology, 1993, 71, 552-557.	0.7	41
497	Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. American Journal of Cardiology, 2002, 89, 924-929.	0.7	41
498	Physicians and the Investment Industry. JAMA - Journal of the American Medical Association, 2005, 293, 2654.	3.8	41
499	Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2011, 162, 98-105.e1.	1.2	41
500	Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation. Journal of Medical Genetics, 2014, 51, 83-89.	1.5	41
501	How Consumers and Physicians View New Medical Technology: Comparative Survey. Journal of Medical Internet Research, 2015, 17, e215.	2.1	41
502	Lessons we have learned from the GUSTO trial. Journal of the American College of Cardiology, 1995, 25, S10-S17.	1.2	40
503	Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. American Heart Journal, 2001, 141, 469-477.	1.2	40
504	Platelet, Not Endothelial, P-Selectin Is Required for Neointimal Formation After Vascular Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1584-1589.	1.1	40

#	Article	IF	Citations
505	Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Journal of the American College of Cardiology, 2005, 45, 1932-1938.	1.2	40
506	Perspectives on Large-Scale Cardiovascular Clinical Trials for the New Millennium. Circulation, 1997, 95, 1072-1082.	1.6	40
507	Dose-Finding, Safety, and Tolerability Study of an Oral Platelet Glycoprotein IIb/IIIa Inhibitor, Lotrafiban, in Patients With Coronary or Cerebral Atherosclerotic Disease. Circulation, 2000, 102, 728-735.	1.6	39
508	Oral Glycoprotein IIb/IIIa Inhibitors. American Journal of Cardiovascular Drugs, 2001, 1, 421-428.	1.0	39
509	Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. American Journal of Cardiology, 2001, 88, 76-79.	0.7	39
510	Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. American Journal of Cardiology, 2003, 92, 136-140.	0.7	39
511	Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. American Journal of Cardiology, 2003, 92, 582-583.	0.7	39
512	Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. American Journal of Cardiology, 2004, 94, 30-34.	0.7	39
513	Polymorphisms A387P in thrombospondinâ€4 and N700S in thrombospondinâ€1 perturb calcium binding sites. FASEB Journal, 2005, 19, 1893-1895.	0.2	39
514	Randomized trials of directional coronary atherectomy: Implications for clinical practice and future investigation. Journal of the American College of Cardiology, 1994, 24, 431-439.	1.2	38
515	Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, Decreases Monocyte Chemoattractant Protein-1 Expression and Neointimal Hyperplasia in the Rabbit Atherosclerotic Balloon Injury Model. Journal of Cardiovascular Pharmacology, 2005, 45, 61-67.	0.8	38
516	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. American Heart Journal, 2008, 155, 910-917.	1.2	38
517	Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity. JACC: Cardiovascular Interventions, 2010, 3, 1001-1007.	1.1	38
518	Digital medicine: empowering both patients and clinicians. Lancet, The, 2016, 388, 740-741.	6.3	38
519	Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). American Journal of Cardiology, 2000, 85, 427-434.	0.7	37
520	Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)â€“2 trial. American Heart Journal, 2006, 151, 1032.e1-1032.e7.	1.2	37
521	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 203-212.	1.1	37
522	Augmenting diagnostic vision with AI. Lancet, The, 2017, 390, 221.	6.3	37

#	Article	IF	Citations
523	Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO IIb and RAPPORT trials. American Heart Journal, 2000, 139, 476-481.	1.2	36
524	Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. American Heart Journal, 2000, 139, 939-944.	1.2	36
525	Î²-Blockers Before Percutaneous Coronary Intervention Do Not Attenuate Postprocedural Creatine Kinase Isoenzyme Rise. Circulation, 2001, 104, 2685-2688.	1.6	36
526	Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes. Circulation, 2001, 104, 2772-2777.	1.6	36
527	Impact of female sex on outcome after percutaneous coronary intervention. American Heart Journal, 2004, 148, 998-1002.	1.2	36
528	Association of Mortality With Years of Education in Patients With ST-Segment Elevation Myocardial Infarction Treated With Fibrinolysis. Journal of the American College of Cardiology, 2011, 57, 138-146.	1.2	36
529	More on the GUSTO Trial. New England Journal of Medicine, 1994, 331, 277-278.	13.9	35
530	Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes. American Heart Journal, 1999, 138, 1073-1081.	1.2	35
531	Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. American Heart Journal, 2001, 141, 391-401.	1.2	35
532	Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. American Journal of Cardiology, 2002, 89, 937-940.	0.7	35
533	International variation in the use of evidence-based medicines for acute coronary syndromes. European Heart Journal, 2003, 24, 2133-2141.	1.0	35
534	Emerging Genomic Applications in Coronary Artery Disease. JACC: Cardiovascular Interventions, 2011, 4, 473-482.	1.1	35
535	Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute Myocardial Infarction. American Journal of Cardiology, 1995, 76, 1007-1013.	0.7	34
536	Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. Journal of the American College of Cardiology, 2002, 40, 669-675.	1.2	34
537	Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. American Journal of Cardiology, 2002, 90, 1374-1377.	0.7	34
538	Outcome of Multivessel Coronary Intervention in the Contemporary Percutaneous Revascularization Era. American Journal of Cardiology, 2006, 97, 1585-1590.	0.7	34
539	Angiographic Adverse Events, Creatine Kinase-MB Elevation, and Ischemic End Points Complicating Percutaneous Coronary Intervention (a REPLACE-2 Substudy). American Journal of Cardiology, 2006, 97, 1591-1596.	0.7	34
540	Mortality, kidney disease and cardiac procedures following acute coronary syndrome. Nephrology Dialysis Transplantation, 2007, 23, 934-940.	0.4	34

#	Article	IF	Citations
541	Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level. Genome Biology, 2010, 11, R118.	13.9	34
542	Distinct Effects of Recombinant Desulfatohirudin (Revasc) and Heparin on Plasma Levels of Fibrinopeptide A and Prothrombin Fragment F1.2 in Unstable Angina. Circulation, 1996, 94, 2389-2395.	1.6	34
543	Results of directional coronary atherectomy during multicenter preapproval testing. American Journal of Cardiology, 1993, 72, E6-E11.	0.7	33
544	Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model. International Journal of Cardiology, 1999, 68, S85-S91.	0.8	33
545	Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. American Heart Journal, 1999, 137, 612-620.	1.2	33
546	Aspirin with Bypass Surgery â€" From Taboo to New Standard of Care. New England Journal of Medicine, 2002, 347, 1359-1360.	13.9	33
547	Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	33
548	Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. American Journal of Cardiology, 2004, 94, 623-625.	0.7	33
549	Real-world bare metal stenting: Identification of patients at low or very low risk of 9-month coronary revascularization. Catheterization and Cardiovascular Interventions, 2004, 63, 135-140.	0.7	33
550	Bivalirudin vs Heparin in Percutaneous Coronary Intervention: A Pooled Analysis. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, 209-216.	1.0	33
551	Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986â€"1987 versus 1991: Improved in-hospital and 12-month results. Journal of the American College of Cardiology, 1995, 25, 1137-1142.	1.2	32
552	Directional atherectomy versus balloon angioplasty for coronary ostial and nonostial left anterior descending coronary artery lesions: Results from a randomized multicenter trial. Journal of the American College of Cardiology, 1995, 25, 1380-1386.	1.2	32
553	Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. Journal of the American College of Cardiology, 1995, 26, 1651-1656.	1.2	32
554	ANTIPLATELET AND ANTICOAGULANT THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC HEART DISEASE. Medical Clinics of North America, 2000, 84, 163-179.	1.1	32
555	Recombinant Soluble P-Selectin Glycoprotein Ligand-Ig (rPSGL-Ig) Attenuates Infarct Size and Myeloperoxidase Activity in a Canine Model of Ischemia-Reperfusion. Thrombosis and Haemostasis, 2002, 88, 149-154.	1.8	32
556	The rudimentary phase of personalised medicine: coronary risk scores. Lancet, The, 2003, 362, 1776-1777.	6.3	32
557	A genome sequencing program for novel undiagnosed diseases. Genetics in Medicine, 2015, 17, 995-1001.	1.1	32
558	Polygenic Risk Scores Expand to Obesity. Cell, 2019, 177, 518-520.	13.5	32

#	Article	IF	Citations
559	Exercise testing three days after onset of acute myocardial infarction. American Journal of Cardiology, 1987, 60, 958-962.	0.7	31
560	Results of percutaneous transluminal coronary angioplasty of high-risk angulated stenoses. American Journal of Cardiology, 1990, 66, 932-937.	0.7	31
561	The Stentor and the sea change. American Journal of Cardiology, 1995, 76, 307-308.	0.7	31
562	Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. Journal of the American College of Cardiology, 1998, 32, 936-941.	1.2	31
563	The benefit of abciximab in percutaneous coronary revascularization is not device-specific. American Journal of Cardiology, 2000, 85, 1060-1064.	0.7	31
564	Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization. Circulation, 2000, 102, 2923-2929.	1.6	31
565	Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). American Journal of Cardiology, 2002, 90, 916-921.	0.7	31
566	The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. Journal of Thrombosis and Thrombolysis, 2002, 14, 91-101.	1.0	31
567	Current Status and Future Prospects for Acute Myocardial Infarction Therapy. Circulation, 2003, 108, 6III--13.	1.6	31
568	Integrative medicine: implementation and evaluation of a professional development program using experiential learning and conceptual change teaching approaches. Patient Education and Counseling, 2006, 62, 5-12.	1.0	31
569	Peroxisome proliferatorâ€“activated receptor Î³ agonists for the Prevention of Adverse events following percutaneous coronary Revascularizationâ€”results of the PPAR Study. American Heart Journal, 2007, 154, 137-143.	1.2	31
570	Genetic determinants of phenotypic diversity in humans. Genome Biology, 2008, 9, 215.	13.9	31
571	The Healthy Pregnancy Research Program: transforming pregnancy research through a ResearchKit app. Npj Digital Medicine, 2018, 1, 45.	5.7	31
572	Conjunctive Use of Platelet Glycoprotein IIb/IIIa Antagonists and Thrombolytic Therapy for Acute Myocardial Infarction. Thrombosis and Haemostasis, 1997, 78, 214-219.	1.8	31
573	An analysis of the cause of early mortality after administration of thrombolytic therapy. Coronary Artery Disease, 1993, 4, 957-964.	0.3	30
574	Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIbIIIa inhibitors. American Heart Journal, 1995, 130, 666-672.	1.2	30
575	TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: A pooled analysis. American Heart Journal, 1997, 133, 273-282.	1.2	30
576	A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study. American Heart Journal, 2000, 140, 722-726.	1.2	30

#	Article	IF	Citations
577	Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. Journal of the American College of Cardiology, 2001, 37, 492-498.	1.2	30
578	Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease. Journal of Medical Genetics, 2006, 44, 161-165.	1.5	30
579	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Archives of Cardiovascular Diseases, 2009, 102, 485-496.	0.7	30
580	Catapulting clopidogrel pharmacogenomics forward. Nature Medicine, 2011, 17, 40-41.	15.2	30
581	Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?. Circulation: Cardiovascular Interventions, 2012, 5, 77-81.	1.4	30
582	The big medical data miss: challenges in establishing an open medical resource. Nature Reviews Genetics, 2015, 16, 253-254.	7.7	30
583	Mechanical activation of noncoding-RNA-mediated regulation of disease-associated phenotypes in human cardiomyocytes. Nature Biomedical Engineering, 2019, 3, 137-146.	11.6	30
584	One-year outcome after therapy with tissue plasminogen activator: Report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. American Heart Journal, 1990, 119, 777-785.	1.2	29
585	Importance of microembolization and inflammation in atherosclerotic heart disease. American Heart Journal, 2000, 140, S90-S102.	1.2	29
586	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2005, 150, 401.e1-401.e7.	1.2	29
587	Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial. Value in Health, 2009, 12, 872-879.	0.1	29
588	Clinical Implications of Human Population Differences in Genome-Wide Rates of Functional Genotypes. Frontiers in Genetics, 2012, 3, 211.	1.1	29
589	Can Hospital Rounds With Pocket Ultrasound By Cardiologists Reduce Standard Echocardiography?. American Journal of Medicine, 2014, 127, 669.e1-669.e7.	0.6	29
590	Association of Sleep Duration and Variability With Body Mass Index. JAMA Internal Medicine, 2020, 180, 1694.	2.6	29
591	Self-Monitoring Utilization Patterns Among Individuals in an Incentivized Program for Healthy Behaviors. Journal of Medical Internet Research, 2016, 18, e292.	2.1	29
592	The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization. Journal of the American College of Cardiology, 1999, 33, 647-653.	1.2	28
593	Effect of anti-tumor necrosis factor-Î± polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis, 2002, 161, 153-159.	0.4	28
594	Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. American Journal of Cardiology, 2002, 89, 1209-1211.	0.7	28

#	Article	IF	Citations
595	Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease: Reply. Journal of the American College of Cardiology, 2003, 42, 1336-1337.	1.2	28
596	Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting. American Journal of Cardiology, 2005, 95, 791-795.	0.7	28
597	Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. American Heart Journal, 2006, 152, 149-154.	1.2	28
598	Impact of Sex, Metabolic Syndrome, and Diabetes Mellitus on Cardiovascular Events. American Journal of Cardiology, 2007, 100, 227-233.	0.7	28
599	Characteristics of Genomic Test Consumers Who Spontaneously Share Results With Their Health Care Provider. Health Communication, 2014, 29, 105-108.	1.8	28
600	Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. Physical Biology, 2014, 11, 016002.	0.8	28
601	Long-Term Follow-Up of Gender-Specific Outcomes After Thrombolytic Therapy for Acute Myocardial Infarction from the GUSTO-I Trial. Journal of Women's Health, 1997, 6, 285-293.	0.9	27
602	Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. American Journal of Cardiology, 1999, 84, 728-730.	0.7	27
603	Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. American Journal of Cardiology, 2001, 88, 1403-1406.	0.7	27
604	Early angioplasty in acute coronary syndromes without persistent st-segment elevation improves outcome but increases the need for six-month repeat revascularization. Journal of the American College of Cardiology, 2002, 39, 1924-1929.	1.2	27
605	Pharmacogenomics in cardiovascular diseases. Progress in Cardiovascular Diseases, 2002, 44, 479-498.	1.6	27
606	Angiographic variables predict increased riskfor adverse ischemic events after coronarystenting with glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology, 2003, 42, 981-988.	1.2	27
607	Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine. Journal of the American College of Cardiology, 2007, 49, 279-289.	1.2	27
608	Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2009, 2, 503-512.	1.4	27
609	A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: Results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) Trial. American Heart Journal, 2012, 164, 320-326.	1.2	27
610	Assessing the human immune response to SARS-CoV-2 variants. Nature Medicine, 2021, 27, 571-572.	15.2	27
611	Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology, 1996, 28, 106-111.	1.2	26
612	Benefit of Early Sustained Reperfusion in Patients With Prior Myocardial Infarction (The GUSTO-I) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.7	26

#	Article	IF	Citations
613	Recurrent Ischemia After Thrombolysis: Importance of Associated Clinical Findings fn1fn1This study was supported by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology, 1998, 31, 94-102.	1.2	26
614	Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Journal of the American College of Cardiology, 2001, 37, 1001-1007.	1.2	26
615	Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology, 2004, 43, 542-548.	1.2	26
616	Outcomes in African Americans and whites after percutaneous coronary intervention. American Journal of Medicine, 2005, 118, 1019-1025.	0.6	26
617	Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials. American Heart Journal, 2006, 151, 16-24.	1.2	26
618	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Stroke in Patients with a History of Atrial Fibrillation: Subgroup Analysis of the CHARISMA Randomized Trial. Cerebrovascular Diseases, 2008, 25, 344-347.	0.8	26
619	The digitised clinical trial. Lancet, The, 2017, 390, 2135.	6.3	26
620	Molecular Autopsy for Sudden Death in the Young: Is Data Aggregation the Key?. Frontiers in Cardiovascular Medicine, 2017, 4, 72.	1.1	26
621	Selective Inhibition of Factor Xa Is More Efficient Than Factor VIIaâ€“Tissue Factor Complex Blockade at Facilitating Coronary Thrombolysis in the Canine Model. Journal of the American College of Cardiology, 1996, 28, 1858-1865.	1.2	25
622	Antiplatelet and anticoagulant use after myocardial infarction. Clinical Cardiology, 1996, 19, 357-365.	0.7	25
623	Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. American Journal of Cardiology, 1997, 80, 1075-1077.	0.7	25
624	Higher T-Wave Amplitude Associated With Better Prognosis in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction (a GUSTO-I Substudy) 11This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. American Journal of Cardiology, 1998, 81, 1078-1084.	0.7	25
625	Reperfusion revisited: Beyond TIMI3 flow. Clinical Cardiology, 1999, 22, 20-29.	0.7	25
626	Administration of Recombinant P-Selectin Glycoprotein Ligand Fc Fusion Protein Suppresses Inflammation and Neointimal Formation in Zucker Diabetic Rat Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1598-1603.	1.1	25
627	Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. European Heart Journal, 2005, 26, 2524-2528.	1.0	25
628	Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). American Journal of Cardiology, 2005, 95, 611-614.	0.7	25
629	Comparative gene expression analysis between coronary arteries and internal mammary arteries identifies a role for the TES gene in endothelial cell functions relevant to coronary artery disease. Human Molecular Genetics, 2012, 21, 1364-1373.	1.4	25
630	Cystic fibrosis in an era of genomically guided therapy. Human Molecular Genetics, 2012, 21, R66-R71.	1.4	25

#	Article	IF	Citations
631	Guiding ultrasound image capture with artificial intelligence. Lancet, The, 2020, 396, 749.	6.3	25
632	The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. Journal of Invasive Cardiology, 2006, 18, 115-9.	0.4	25
633	Use of Evidence-Based Medical Therapy in Patients Undergoing Percutaneous Coronary Revascularization in the United States, Europe, and Canada. American Journal of Cardiology, 1997, 79, 867-872.	0.7	24
634	Effects of Stroke on Medical Resource Use and Costs in Acute Myocardial Infarction. Circulation, 1999, 99, 370-376.	1.6	24
635	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. European Heart Journal, 2005, 26, 2396-2403.	1.0	24
636	Genetic structure of community acquired methicillin-resistant Staphylococcus aureus USA300. BMC Genomics, 2012, 13, 508.	1.2	24
637	Comparison of Incidence of Bleeding and Mortality of Men Versus Women With ST-Elevation Myocardial Infarction Treated With Fibrinolysis. American Journal of Cardiology, 2012, 109, 320-326.	0.7	24
638	Validation of a genetic risk score for atrial fibrillation: A prospective multicenter cohort study. PLoS Medicine, 2018, 15, e1002525.	3.9	24
639	Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trial. Contemporary Clinical Trials Communications, 2019, 14, 100318.	0.5	24
640	Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands. Npj Digital Medicine, 2022, 5, 49.	5.7	24
641	Correlates of in-hospital cost among patients undergoing abdominal aortic aneurysm repair. American Heart Journal, 1998, 136, 696-702.	1.2	23
642	Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. American Heart Journal, 2000, 140, 385-394.	1.2	23
643	Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. American Journal of Cardiology, 2001, 87, 532-536.	0.7	23
644	Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. American Journal of Medicine, 2003, 115, 318-321.	0.6	23
645	Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. American Journal of Cardiology, 2004, 94, 190-192.	0.7	23
646	Deficiency of LRP8 in mice is associated with altered platelet function and prolonged time for in vivo thrombosis. Thrombosis Research, 2009, 123, 644-652.	0.8	23
647	The Lost Decade of Nesiritide. New England Journal of Medicine, 2011, 365, 81-82.	13.9	23
648	Evolution of improved antithrombotic and antiplatelet agents: genesis of the comparison of abciximab complications with hirulog [and back-up abciximab] events trial (CACHET). American Journal of Cardiology, 1998, 82, 63P-68P.	0.7	22

#	Article	IF	Citations
649	Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). American Journal of Cardiology, 2004, 93, 458-461.	0.7	22
650	ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 69	0.7	22
651	Molecular Mechanisms of Myocardial Infarction. Current Problems in Cardiology, 2005, 30, 333-374.	1.1	22
652	Molecular genetics of atrial fibrillation. Genome Medicine, 2009, 1, 54.	3.6	22
653	Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients. Stroke, 2010, 41, 1679-1683.	1.0	22
654	AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353â€‰157 patients in London, UK. BMJ Open, 2022, 12, e058552.	0.8	22
655	Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1988, 12, A58-A68.	1.2	21
656	Comparison of three coronary stents: Clinical and angiographic outcome after elective placement in 134 consecutive patients. Catheterization and Cardiovascular Diagnosis, 1994, 33, 199-204.	0.7	21
657	711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization. Journal of the American College of Cardiology, 1995, 25, 80A-81A.	1.2	21
658	Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-I. American Heart Journal, 1998, 136, 868-876.	1.2	21
659	The Future of Antiplatelet Therapy: Optimizing Management in Patients with Acute Coronary Syndrome. Clinical Cardiology, 2000, 23, 23-28.	0.7	21
660	Annotating individual human genomes. Genomics, 2011, 98, 233-241.	1.3	21
661	Medicine Unplugged: The Future of Laboratory Medicine. Clinical Chemistry, 2012, 58, 1644-1647.	1.5	21
662	Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial. Journal of Cardiovascular Translational Research, 2012, 5, 366-374.	1.1	21
663	A Novel Molecular Diagnostic Marker for Familial and Early-Onset Coronary Artery Disease and Myocardial Infarction in the LRP8 Gene. Circulation: Cardiovascular Genetics, 2014, 7, 514-520.	5.1	21
664	Has SARS-CoV-2 reached peak fitness?. Nature Medicine, 2021, 27, 1323-1324.	15.2	21
665	Absence of Increased In-hospital Complications With Reused Balloon Catheters. American Journal of Cardiology, 1996, 78, 717-719.	0.7	20
666	Clinical risk factors for ischemic complications after percutaneous coronary interventions: Results from the EPIC trial. American Heart Journal, 1999, 137, 264-273.	1.2	20

#	Article	IF	Citations
667	A guide to therapeutic decision-making in patients with nonâ€“ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, S123-S129.	1.2	20
668	Association of directâ€toâ€consumer genomeâ€wide disease risk estimates and selfâ€reported disease. Genetic Epidemiology, 2012, 36, 66-70.	0.6	20
669	Selection of dilatation hardware for ptca-1985. Catheterization and Cardiovascular Diagnosis, 1985, 11, 629-637.	0.7	19
670	Influence of a Randomized Clinical Trial on Practice by Participating Investigators: Lessons From the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT) fn1fn1To discuss this article on-line, visit the ACC Home Page at www.acc.org/membersand click on the JACC Forum. Journal of the American College of Cardiology, 1998, 31, 265-272.	1.2	19
671	Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. European Heart Journal, 2007, 28, 425-432.	1.0	19
672	Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials. Journal of Biopharmaceutical Statistics, 2010, 20, 315-333.	0.4	19
673	Applicability of percutaneous transluminal coronary angioplasty to patients with recombinant tissue plasminogen activator mediated thrombolysis. Catheterization and Cardiovascular Diagnosis, 1985, 11, 337-348.	0.7	18
674	Coronary Revascularization Surgery After Myocardial Infarction: Impact of Bypass Surgery on Survival After Thrombolysis. Journal of the American College of Cardiology, 1997, 29, 240-249.	1.2	18
675	Predictors of left ventricular function after acute myocardial infarction: Effects of time to treatment, patency, and body mass index. American Heart Journal, 2001, 142, 43-50.	1.2	18
676	Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. Journal of the American College of Cardiology, 2002, 40, 1034-1040.	1.2	18
677	abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. American Journal of Cardiology, 2002, 90, 628-630.	0.7	18
678	Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. American Journal of Cardiology, 2005, 95, 716-721.	0.7	18
679	The Collapse. Journal of the American College of Cardiology, 2010, 56, 1564-1566.	1.2	18
680	Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals. Heart Rhythm, 2019, 16, 26-30.	0.3	18
681	Conquering Atherosclerotic Cardiovascular Disease â€” 50 Years of Progress. New England Journal of Medicine, 2021, 384, 785-788.	13.9	18
682	Advances in Thrombolytic Therapy for Acute Myocardial Infarction. Journal of Clinical Pharmacology, 1987, 27, 735-745.	1.0	17
683	Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. American Heart Journal, 1996, 131, 211-218.	1.2	17
684	Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization. Annals of the New York Academy of Sciences, 1997, 811, 255-288.	1.8	17

#	Article	IF	Citations
685	A profile of candidates for repeat myocardial revascularization: Implications for selection of treatment. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 153-161.	0.4	17
686	Update on Clinical Trials of Antiplatelet Therapy for Cerebrovascular Diseases. Cerebrovascular Diseases, 2000, 10, 34-40.	0.8	17
687	The role of low-moleculaâ€“weight heparin in cardiovascular diseases. Progress in Cardiovascular Diseases, 2002, 45, 139-156.	1.6	17
688	Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. Catheterization and Cardiovascular Interventions, 2002, 57, 476-483.	0.7	17
689	Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. American Journal of Cardiology, 2003, 92, 1468-1471.	0.7	17
690	An invasive strategy is associated with decreased mortality in patients with unstable angina and nonâ€“ST-elevation myocardial infarction: GUSTO IIb trial. American Journal of Medicine, 2003, 114, 106-111.	0.6	17
691	Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade. Journal of the American College of Cardiology, 2004, 44, 1194-1199.	1.2	17
692	The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice. Catheterization and Cardiovascular Interventions, 2006, 67, 563-570.	0.7	17
693	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	3.7	17
694	Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. European Heart Journal, 2005, 26, 1506-1512.	1.0	16
695	Risk for Cardiovascular Outcomes among Subjects with Atherosclerotic Cardiovascular Disease and Greater-than-Normal Estimated Glomerular Filtration Rate. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1215-1222.	2.2	16
696	Direct-to-Consumer Genetic Testing: Reliable or Risky?. Clinical Chemistry, 2011, 57, 1641-1644.	1.5	16
697	Is my cough COVID-19?. Lancet, The, 2020, 396, 1874.	6.3	16
698	Impact of polygenic risk communication: an observational mobile application-based coronary artery disease study. Npj Digital Medicine, 2022, 5, 30.	5.7	16
699	Acute intervention during myocardial infarction in patients with prior coronary bypass surgery. American Journal of Cardiology, 1990, 65, 924-926.	0.7	15
700	Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1999, 34, 1729-1737.	1.2	15
701	Optimizing Percutaneous Coronary Revascularization in Diabetic Women: Analysis from the EPISTENT Trial. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 741-746.	1.7	15
702	The fibrillin-1 gene: unlocking new therapeutic pathways in cardiovascular disease. Heart, 2013, 99, 83-90.	1.2	15

#	Article	IF	Citations
703	A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). American Journal of Cardiology, 2000, 85, 692-697.	0.7	14
704	Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal proâ€“B-type natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. American Heart Journal, 2007, 153, 36-41.	1.2	14
705	The next phase in human genetics. Nature Biotechnology, 2011, 29, 38-39.	9.4	14
706	Rebooting Cancer Tissue Handling in the Sequencing Era. JAMA - Journal of the American Medical Association, 2013, 309, 37.	3.8	14
707	Off the cuff: rebooting blood pressure treatment. Lancet, The, 2016, 388, 749.	6.3	14
708	Miscues on the "lack of MEF2A mutations" in coronary artery disease. Journal of Clinical Investigation, 2005, 115, 1399-1400.	3.9	14
709	Percutaneous revascularization of ostial saphenous vein graft stenoses. Journal of the American College of Cardiology, 1995, 26, 955-960.	1.2	13
710	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. , 1997, 42, 102-108.		13
711	Recent advances in anticoagulant therapy for acute coronary syndromes. American Heart Journal, 2001, 142, S22-S29.	1.2	13
712	Abciximab-facilitated percutaneous coronary intervention and long-term survivalâ€”a prospective single-center registry. European Heart Journal, 2003, 24, 630-638.	1.0	13
713	The genetics of heart attack. Heart, 2005, 92, 855-861.	1.2	13
714	Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)â€“2 trial. American Heart Journal, 2006, 152, 157-163.	1.2	13
715	Pharmacy Benefit Managers, Pharmacies, and Pharmacogenomic Testing: Prescription for Progress?. Science Translational Medicine, 2010, 2, 44cm22.	5.8	13
716	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart, 2011, 97, 626-631.	1.2	13
717	Multi-allelic haplotype association identifies novel information different from single-SNP analysis: A new protective haplotype in the LRP8 gene is against familial and early-onset CAD and MI. Gene, 2013, 521, 78-81.	1.0	13
718	Toward superhuman SARS-CoV-2 immunity?. Nature Medicine, 2021, 27, 5-6.	15.2	13
719	A framework for smartphone-enabled, patient-generated health data analysis. PeerJ, 2016, 4, e2284.	0.9	13
720	Reuse of coronary angioplasty equipment: Technical and clinical issues. American Heart Journal, 1996, 131, 624-630.	1.2	12

#	Article	IF	Citations
721	Effects of Thrombolytic Regimen, Early Catheterization, and Predischarge Angiographic Variables on Six-Week Left Ventricular Function. American Journal of Cardiology, 1997, 79, 539-544.	0.7	12
722	Cost of Cardiac Care in the Three Years After Coronary Catheterization in a Contained Care System: Critical Determinants and Implications 11Financial support of this project was provided by the Office of Quality Management, The Cleveland Clinic Foundation, Cleveland, Ohio.. Journal of the American College of Cardiology, 1998, 31, 1306-1313.	1.2	12
723	Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb. American Heart Journal, 1999, 137, 12-23.	1.2	12
724	Coronary artery imaging with multidetector computed tomography: A call for an evidence-based, multidisciplinary approach. American Heart Journal, 2006, 151, 945-948.	1.2	12
725	Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial). American Journal of Cardiology, 2008, 102, 1285-1290.	0.7	12
726	Identification of a novel locus for triglyceride on chromosome 1p31-32 in families with premature CAD and MI. Journal of Lipid Research, 2008, 49, 1034-1038.	2.0	12
727	Genome-Wide Linkage Analysis of Large Multiple Multigenerational Families Identifies Novel Genetic Loci for Coronary Artery Disease. Scientific Reports, 2017, 7, 5472.	1.6	12
728	Pathology of unstable angina: Analysis of biopsies obtained by directional coronary atherectomy. Journal of Thrombosis and Thrombolysis, 1994, 1, 63-71.	1.0	11
729	Cardiogenic shock: Current understandings and future research directions. American Journal of Cardiology, 1994, 74, 724-726.	0.7	11
730	Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II. Journal of the American College of Cardiology, 1996, 27, 83.	1.2	11
731	Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. , 1999, 7, 227-231.		11
732	An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. Journal of Thrombosis and Thrombolysis, 2002, 14, 33-42.	1.0	11
733	Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. European Heart Journal, 2005, 26, 128-136.	1.0	11
734	The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience. American Heart Journal, 2006, 152, 277-284.	1.2	11
735	A genome-wide linkage scan identifies multiple quantitative trait loci for HDL-cholesterol levels in families with premature CAD and MI. Journal of Lipid Research, 2010, 51, 1442-1451.	2.0	11
736	Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial. American Heart Journal, 2010, 160, 678-684.	1.2	11
737	<emph type="ital">CYP2C19</emph> Genotype and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2012, 307, 1482.	3.8	11
738	A Call to Action. American Journal of Preventive Medicine, 2013, 44, S54-S57.	1.6	11

#	Article	IF	Citations
739	To truly look inside. Lancet, The, 2016, 387, 1268-1269.	6.3	11
740	Real world usage characteristics of a novel mobile health self-monitoring device: Results from the Scanadu Consumer Health Outcomes (SCOUT) Study. PLoS ONE, 2019, 14, e0215468.	1.1	11
741	Three year clinical outcomes in a nationwide, observational, siteless clinical trial of atrial fibrillation screeningâ€"mHealth Screening to Prevent Strokes (mSToPS). PLoS ONE, 2021, 16, e0258276.	1.1	11
742	Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution. American Journal of Medicine, 2000, 108, 176-177.	0.6	10
743	Recurrent ischemia after thrombolysis for acute myocardial infarction. American Heart Journal, 2001, 141, 559-565.	1.2	10
744	Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. American Heart Journal, 2001, 141, 599-602.	1.2	10
745	Genetic testing for coronary heart disease: the approaching frontier. Expert Review of Molecular Diagnostics, 2002, 2, 448-460.	1.5	10
746	Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. American Heart Journal, 2002, 143, 1040-1045.	1.2	10
747	Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. American Journal of Cardiology, 2002, 90, 1198-1203.	0.7	10
748	Pharmaceutical advertising versus research spending: are profits more important than patients?. American Heart Journal, 2003, 146, 563-564.	1.2	10
749	Cholesterol, racial variation and targeted medicines. Nature Medicine, 2005, 11, 122-123.	15.2	10
750	Warfarin Pharmacogenomics: A big step forward for individualized medicine: enlightened dosing of warfarin. European Journal of Human Genetics, 2008, 16, 532-534.	1.4	10
751	Digitising the mind. Lancet, The, 2017, 389, 1877.	6.3	10
752	Monitoring Jet Engines and the Health of People. JAMA - Journal of the American Medical Association, 2018, 320, 2309.	3.8	10
753	A skin patch for sensing blood pressures. Nature Biomedical Engineering, 2018, 2, 633-634.	11.6	10
754	Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program. Stem Cell Research, 2020, 46, 101803.	0.3	10
755	Relation of insurance status to performance of coronary angiography in patients with unstable angina pectoris or acute myocardial infarction. American Journal of Cardiology, 2003, 91, 721-723.	0.7	9
756	Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomesâ€"observations from the TARGET trial. American Journal of Cardiology, 2003, 92, 125-129.	0.7	9

#	Article	IF	Citations
757	Home Monitoring of Blood Pressure: Shortâ€"Term Changes During Serial Measurements for 56398 Subjects. IEEE Journal of Biomedical and Health Informatics, 2018, 22, 1691-1698.	3.9	9
758	Digital orthodoxy of human data collection. Lancet, The, 2019, 394, 556.	6.3	9
759	901-14 Impact of Ionic and Non-ionic Contrast Media on Post-PTCA Ischemic Complications: Results from the EPIC Trial. Journal of the American College of Cardiology, 1995, 25, 8A.	1.2	8
760	Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). American Heart Journal, 1999, 137, 227-233.	1.2	8
761	Risk reduction with long-term clopidogrel following percutaneous coronary intervention. European Heart Journal, 2004, 25, 2169-2170.	1.0	8
762	The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: Insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. American Heart Journal, 2005, 150, 89-93.	1.2	8
763	Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. Catheterization and Cardiovascular Interventions, 2006, 68, 352-356.	0.7	8
764	Past the wall in cardiovascular R&D. Nature Reviews Drug Discovery, 2009, 8, 259-259.	21.5	8
765	Genome-Wide Association of Implantable Cardioverter-Defibrillator Activation With Life-Threatening Arrhythmias. PLoS ONE, 2012, 7, e25387.	1.1	8
766	Genome-Wide Linkage Scan Identifies Two Novel Genetic Loci for Coronary Artery Disease: In GeneQuest Families. PLoS ONE, 2014, 9, e113935.	1.1	8
767	Analysis of causal effect of APOA5 variants on premature coronary artery disease. Annals of Human Genetics, 2018, 82, 437-447.	0.3	8
768	Adjunctive Therapy for Percutaneous Revascularization in Acute Myocardial Infarction. Current Pharmaceutical Design, 2004, 10, 399-405.	0.9	8
769	The Restenosis â€œAntitheoryâ€• Mayo Clinic Proceedings, 1993, 68, 88-90.	1.4	7
770	Potential value of platelet GPIIb/IIIa antagonist for treating heparin-induced thrombocytopenia (HIT). Journal of the American College of Cardiology, 1996, 27, 316.	1.2	7
771	Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion. Journal of Thrombosis and Thrombolysis, 1997, 4, 259-266.	1.0	7
772	Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. American Journal of Cardiology, 1998, 82, 1105-1106.	0.7	7
773	Acute myocardial infarction after aortic valve endocarditis. American Journal of Medicine, 2001, 110, 417-418.	0.6	7
774	Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). American Journal of Cardiology, 2002, 89, 1429-1431.	0.7	7

#	Article	IF	Citations
775	Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. American Journal of Cardiology, 2003, 91, 742-743.	0.7	7
776	Anticoagulation With Prosthetic Cardiac Valves. Archives of Internal Medicine, 2003, 163, 2251.	4.3	7
777	Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 206-215.	6.6	7
778	Medicine and meteorology: Cloud, connectivity, and care. Lancet, The, 2020, 395, 1334.	6.3	7
779	What's lurking in your electrocardiogram?. Lancet, The, 2021, 397, 785.	6.3	7
780	Î±IIbÎ²3 (GPIIb-IIIa) Antagonists. , 2007, , 1145-1163.		7
781	Should Older Patients with Acute Myocardial Infarction Receive Thrombolytic Therapy?. Drugs and Aging, 1992, 2, 461-468.	1.3	6
782	Uncoupling clinical outcomes and coronary angiography: A review and perspective of recent trials in coronary artery disease. American Heart Journal, 1996, 132, 910-920.	1.2	6
783	Prospective Use of Glycoprotein IIb/IIIa Receptor Blockers in the Emergency Department Setting. Annals of Emergency Medicine, 1998, 32, 712-722.	0.3	6
784	Coronary stenting and use of abciximab. Lancet, The, 1998, 352, 1311-1312.	6.3	6
785	What role for catheter laboratories in unstable angina?. Lancet, The, 1998, 352, 500-501.	6.3	6
786	The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. American Heart Journal, 1999, 137, S90-S93.	1.2	6
787	Glycoprotein IIb/IIIa inhibitors: current indications and future prospects. American Journal of Medicine, 2000, 109, 252-254.	0.6	6
788	Characteristics, Treatment and Outcome of Patients with Non-ST-Elevation Acute Coronary Syndromes and Multivessel Coronary Artery Disease: Observations from PURSUIT (Platelet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Tc 2002, 98, 195-201.	0.6	6
789	Cardiology and emergency medicine: United We Stand, divided we fall. Annals of Emergency Medicine, 2002, 39, 164-167.	0.3	6
790	A matter of life and death? The Heart Protection Study and protection of clinical trial participants. Contemporary Clinical Trials, 2003, 24, 501-505.	2.0	6
791	Creation of a large-scale genetic data bank for cardiovascular association studies. American Heart Journal, 2005, 150, 500-506.	1.2	6
792	Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction. American Journal of Cardiology, 2008, 102, 1119-1124.	0.7	6

#	Article	IF	Citations
793	Point-of-care genetic testingâ€"a new frontier explored. Nature Reviews Cardiology, 2012, 9, 315-316.	6.1	6
794	It takes a planet. Nature Biotechnology, 2019, 37, 858-861.	9.4	6
795	On the Effectiveness of Deep Representation Learning: The Atrial Fibrillation Case. Computer, 2019, 52, 18-29.	1.2	6
796	Long data from the electrocardiogram. Lancet, The, 2019, 393, 2189.	6.3	6
797	Direct to Consumer Fitness DNA Testing. Clinical Chemistry, 2019, 65, 45-47.	1.5	6
798	Lack of Cardioprotective Effect of Naproxen. Archives of Internal Medicine, 2002, 162, 2637-2637.	4.3	6
799	An ensemble method for gene discovery based on DNA mi-croarray data. Science in China Series C: Life Sciences, 2004, 47, 396.	1.3	6
800	Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute Myocardial Infarction. Catheterization and Cardiovascular Diagnosis, 1990, 20, 221-226.	0.7	5
801	701-6 Dissociation Between Minimal Luminal Diameter and Clinical Outcome at 6 Month Follow-up in Randomized Trials of Percutaneous Revascularization. Journal of the American College of Cardiology, 1995, 25, 36A.	1.2	5
802	Another step toward resolving the contrast controversy. Journal of the American College of Cardiology, 1996, 27, 1387-1389.	1.2	5
803	Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. American Journal of Cardiology, 1996, 78, 1338-1344.	0.7	5
804	The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine. Japanese Circulation Journal, 1998, 62, 233-243.	1.0	5
805	Effect of institutional volume and academic status on outcomes of coronary interventions: The IMPACT-II experience. American Heart Journal, 1999, 138, 976-982.	1.2	5
806	Debate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fight. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 260.	1.5	5
807	Association of race with complications and prognosis following acute coronary syndromes. American Journal of Cardiology, 2004, 94, 792-794.	0.7	5
808	A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: Factoring in new trials and meta-analysis data. American Heart Journal, 2005, 149, S100-S106.	1.2	5
809	Identification of atherosclerosis-modifying genes: pathogenic insights and therapeutic potential. Expert Review of Cardiovascular Therapy, 2006, 4, 703-709.	0.6	5
810	Genome scanning and cardiovascular disease. Heart, 2008, 94, 1361-1363.	1.2	5

#	Article	IF	Citations
811	Comment on â€œThe Predictive Capacity of Personal Genome Sequencingâ€• Science Translational Medicine, 2012, 4, 135le5; author reply 135lr3.	5.8	5
812	Potential for a new coronary thrombolytic plateau. Journal of Thrombosis and Thrombolysis, 1996, 3, 127-134.	1.0	4
813	Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. American Heart Journal, 2000, 140, 29-33.	1.2	4
814	Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes. Progress in Cardiovascular Diseases, 2001, 44, 195-206.	1.6	4
815	Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: Lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. American Heart Journal, 2002, 143, 594-601.	1.2	4
816	Comparison of long-term survival following nonâ€“Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. American Journal of Cardiology, 2002, 89, 751-753.	0.7	4
817	On the Significance of Linkage Studies of Complex Traits: Reply to Newton-Cheh et al.. American Journal of Human Genetics, 2004, 75, 152-154.	2.6	4
818	Convergence of atherosclerosis and Alzheimer's disease. Lancet, The, 2004, 363, 2092.	6.3	4
819	From Dissecting Cadavers to Dissecting Genomes. Science Translational Medicine, 2013, 5, 202ed15.	5.8	4
820	Analysis of the 9p21.3 sequence associated with coronary artery disease reveals a tendency for duplication in a CAD patient. Oncotarget, 2018, 9, 15275-15291.	0.8	4
821	Cardiac rehabilitation in the digital era. Lancet, The, 2021, 398, 16.	6.3	4
822	Healthcare resource utilization following ECG sensor patch screening for atrial fibrillation. Heart Rhythm O2, 2020, 1, 351-358.	0.6	4
823	Left ventricular function assessment and acute myocardial infarction. Current Opinion in Cardiology, 1992, 7, 1035-1046.	0.8	3
824	Second thoughts semantic ambiguity, the â€œnon-â€•nosology and myocardial infarction. Journal of Clinical Epidemiology, 1994, 47, 441-446.	2.4	3
825	Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense. , 1997, 4, 325-327.		3
826	Thrombolytic or Angioplasty Therapy of Evolving Myocardial Infarction?. , 1998, 5, S125-S131.		3
827	Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. Annals of Medicine, 2002, 34, 514-522.	1.5	3
828	Lack of adverse clopidogrelâ€“atorvastatin clinical interaction. American Journal of Cardiology, 2004, 93, 669.	0.7	3

#	Article	IF	Citations
829	Characterization of Myocardial Infarction as an End Point in Two Large Trials of Acute Coronary Syndromes. American Journal of Cardiology, 2005, 95, 1404-1408.	0.7	3
830	Planned Versus Provisional Use of Glycoprotein IIb/IIIa Inhibitors in Smokers Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 97, 1679-1684.	0.7	3
831	Population attributable fraction: Its implications for genetic epidemiology and illness prevention. American Heart Journal, 2007, 154, 607-609.	1.2	3
832	Response to Letter Regarding Article, â€œIncomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Riskâ€• Circulation, 2009, 119, .	1.6	3
833	Author Response to Comment on â€œCharacterization of Circulating Endothelial Cells in Acute Myocardial Infarctionâ€• Science Translational Medicine, 2012, 4, 149lr4.	5.8	3
834	A brighter future for kidney disease?. Lancet, The, 2020, 395, 179.	6.3	3
835	Itâ€™s not too late. Science, 2022, 375, 245-245.	6.0	3
836	Vascular access site complications during angioplasty with glycoprotein IIbIIIa receptor inhibition in the IMPACT II trial. Journal of the American College of Cardiology, 1996, 27, 360.	1.2	2
837	Clinical outcome of â€œhigh-riskâ€•vs â€œelectiveâ€•patients undergoing percutaneous coronary intervention: Results from IMPACT-II. Journal of the American College of Cardiology, 1996, 27, 180-181.	1.2	2
838	Noninvasive testing is done only in low risk patients with unstable angina and non-Q-wave Myocardial Infarction (MI): Results from GUSTO-IIa. Journal of the American College of Cardiology, 1996, 27, 181-182.	1.2	2
839	The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trials: A Decade of Reperfusion Strategies. Journal of Interventional Cardiology, 1996, 9, 89-115.	0.5	2
840	The future of antithrombotic and antiplatelet therapy for ischemic heart disease. American Heart Journal, 1998, 136, s66-s68.	1.2	2
841	Termination of the CRESCENDO trial â€“ Authors' reply. Lancet, The, 2010, 376, 1984-1985.	6.3	2
842	Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From the CHARISMA Trial. Canadian Journal of Cardiology, 2011, 27, 222-231.	0.8	2
843	Digital Medicine and the Scripps Translational Science Institute. Clinical and Translational Science, 2011, 4, 8-9.	1.5	2
844	Pharm-Econogenomics: A New Appraisal. Clinical Chemistry, 2013, 59, 592-594.	1.5	2
845	Study Design and the Drug Development Process. JAMA - Journal of the American Medical Association, 2014, 311, 2023.	3.8	2
846	Antiplatelet therapy in cardiology. , 2002, , 1013-1039.		2

#	Article	IF	Citations
847	Determinants of Left Ventricular Functional Recovery After Thrombolytic Therapy and/or Immediate Coronary Angioplasty in Acute Myocardial Infarction. Journal of Interventional Cardiology, 1988, 1, 167-174.	0.5	1
848	Observational versus randomized medical device testing before and after market approvalâ€"The atherectomy-versus-angioplasty controversy. Contemporary Clinical Trials, 1995, 16, 143-149.	2.0	1
849	Application of a continuous regression model of restenosis to saphenous vein grafts after successful percutaneous transluminal coronary angioplasty or directional coronary atherectomy. Journal of the American College of Cardiology, 2000, 35, 619-623.	1.2	1
850	ANTIPLATELET AND ANTICOAGULANT THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC HEART DISEASE. Cardiology Clinics, 2001, 19, 253-265.	0.9	1
851	Economics and quality of care for patients with acute coronary syndromes: The impending crisis. Clinical Cardiology, 2002, 25, 9-15.	0.7	1
852	First human randomized trial of G-CSF stem cell mobilization to treat large acute myocardial infarctionâ€"preliminary results of a pilot study. International Congress Series, 2004, 1262, 364-367.	0.2	1
853	Association of Height With Outcomes in Patients With Acute Myocardial Infarction Receiving Reperfusion Therapy. American Journal of Cardiology, 2005, 95, 1371-1375.	0.7	1
854	Is there a genetic basis for acute coronary syndrome?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 596-597.	3.3	1
855	Stents and sensibility. Catheterization and Cardiovascular Interventions, 2007, 69, 616-617.	0.7	1
856	Response to Letters Regarding Article, â€œPlatelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trialâ€• Circulation, 2012, 125, .	1.6	1
857	What Should Clinicians Do to Engage the Public About Gene Editing?. AMA Journal of Ethics, 2019, 21, E1089-1097.	0.4	1
858	Courage in a climate of fear. Science Translational Medicine, 2020, 12, .	5.8	1
859	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. Catheterization and Cardiovascular Diagnosis, 1997, 42, 102-108.	0.7	1
860	Primary Angioplasty. Contemporary Cardiology, 1999, , 267-291.	0.0	1
861	The Challenge for Stem Cell Therapy. , 2007, , 1-6.		1
862	Experimental Antiplatelet Therapy. , 2007, , 1193-1208.		1
863	The consumer movement in health care. The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha, 2010, 73, 34-5.	0.1	1
864	Continuous 12-lead ST-segment recovery predicts outcome in acute myocardial infarction better than â€œsnapshotâ€•angiograms of TIMI flow. Journal of Electrocardiology, 1998, 30, 167.	0.4	0

#	Article	IF	Citations
865	Comparing physician-specific two-year patient outcomes after coronary angiography. Journal of the American College of Cardiology, 1999, 33, 1278-1285.	1.2	0
866	Dosing regimen of reteplase and costeffectiveness. Lancet, The, 2001, 358, 1462.	6.3	0
867	Small molecules vs. antibody IIb/IIIa receptor blockade in percutaneous coronary interventions: where is the difference?. ACC Current Journal Review, 2001, 10, 63-66.	0.1	0
868	Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on One-Year Event-Free survival. American Journal of Cardiology, 2003, 91, 587-590.	0.7	0
869	Invisible showers. Catheterization and Cardiovascular Interventions, 2004, 63, 42-43.	0.7	0
870	Study Design and Statistical Issues in Pharmacogenetics Research. Methods in Pharmacology and Toxicology, 2008, , 185-206.	0.1	0
871	Is Computed Tomographic Angiography Prognostic in Patients With Cardiac Symptoms?. Journal of the American College of Cardiology, 2008, 51, 1510.	1.2	0
872	Response to Letter Regarding Article, â€œSmoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Diseaseâ€• Circulation, 2010, 122, .	1.6	0
873	Genomics of Myocardial Infarction. , 2010, , 289-302.		0
874	Coronary Artery Disease and Myocardial Infarction. , 2013, , 516-529.		0
875	Implementation of Mobile Health Toolsâ€”Reply. JAMA - Journal of the American Medical Association, 2014, 311, 1448.	3.8	0
876	More than meets the eye: Using AI to identify reduced heart function by electrocardiograms. Med, 2021, 2, 791-793.	2.2	0
877	Genomics of Myocardial Infarction. , 2009, , 665-679.		0
878	Molecular genetics of atherosclerosis and acute coronary syndromes. , 2011, , 35-43.		0
879	Local Gene and Cell Delivery Devices. , 2007, , 419-442.		0
880	The Cleveland Clinic Foundation interventional summit. Journal of Invasive Cardiology, 2004, 16, 1S.	0.4	0
881	Here and now--state of the art: optimal antithrombotic strategy for percutaneous coronary intervention-panel discussion. Journal of Invasive Cardiology, 2004, 16, 30S-31S.	0.4	0
882	Genetics of myocardial infarction. Journal of Invasive Cardiology, 2004, 16, 32S-35S.	0.4	0

#	Article	IF	Citations
883	The future--panel discussion. Journal of Invasive Cardiology, 2004, 16, 65S-66S.	0.4	0